Document:

Exhibit 10.1

 

Share Exchange Agreement

 

This
Share Exchange Agreement, dated as of July [*], 2017, is made by and among INSPYR THERAPEUTICS, INC., a Delaware corporation (the
“Acquiror Company”), LEWIS AND CLARK PHARMACEUTICALS, INC., a Virginia corporation (the “Company”),
each of the Persons listed on Schedule I hereto that comprise all of the shareholders of the Company, and each of which
is a signatory hereto (the “Shareholders”), each of the Persons listed on Schedule I under the title
“Principals” of the Company, each of which is also a Shareholder, and Robert Thompson, solely in his capacity as a
representative of the Shareholders (the “Shareholders’ Representative”).

 

BACKGROUND

 

WHEREAS,
the Shareholders have agreed to transfer to the Acquiror Company, and the Acquiror Company has agreed to acquire from the Shareholders,
all of the Shares, which Shares constitute 100% of the issued and outstanding shares of the Company, in exchange for shares of
common stock of Acquiror Company equal to 50% of outstanding shares of the Acquiror Company’s Common Stock (assuming the
conversion of all issued and outstanding Acquiror Company Preferred Stock into shares of Acquiror Company Common Stock at the
Closing Date) to be issued on the Closing Date (the “Acquiror Company Shares”), on the terms and conditions
as set forth herein; and

 

WHEREAS,
after giving effect to the transactions contemplated by this Agreement, the Acquiror Company Shares to be issued to the Shareholders
shall constitute 50% of the issued and outstanding shares of the Acquiror Company’s Common Stock (assuming the conversion
of all issued and outstanding Acquiror Company Preferred Stock into shares of Acquiror Company Common Stock at the Closing Date).

 

NOW
THEREFORE in consideration of the premises and the mutual covenants, agreements, representations and warranties contained
herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto
hereby agree as follows:

 

SECTION
I

DEFINITIONS

 

Unless
the context otherwise requires, the terms defined in this Section I will have the meanings herein specified for all purposes
of this Agreement, applicable to both the singular and plural forms of any of the terms herein defined.

 

1.1             
“Accredited Investor” has the meaning set forth in Regulation D under the Securities Act.

 

1.2             
“Acquired Companies” means, collectively, the Company and the Company Subsidiaries.

 

      

     

    

 

1.3             
 “Acquiror Company Board” means the Board of Directors of the Acquiror Company.

 

1.4             
“Acquiror Company Common Stock” means the Acquiror Company’s common stock, par value US $0.0001
per share.

 

1.5             
“Acquiror Company Disclosure Schedules” has a meaning set forth in Section VI.

 

1.6             
“Acquiror Company Indemnified Persons” has the meaning set forth in Section 10.1.

 

1.7             
“Acquiror Company Shares” has the meaning set forth in the recitals.

 

1.8             
“Acquiror Company Preferred Stock” means collectively, the Acquiror Company’s (i) Series A Preferred
Stock, (ii) Series B Preferred Stock and (iii) Series C Preferred Stock.

 

1.9             
“Action” has the meaning set forth in Section 5.17.

 

1.10         
“Affiliate” means, with respect to any Person, any other Person who, directly or indirectly, controls,
is controlled by, or is under common control with such Person, including any general partner, managing member, officer or director
of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing
members of, or shares the same management company with, such Person.

 

1.11         
“Agreement” means this Share Exchange Agreement, including all Schedules and Exhibits hereto, as this
Share Exchange Agreement may be from time to time amended, modified or supplemented.

 

1.12         
“Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy.”

 

1.13         
“Cause” means, with respect to an individual, such individual has (i) breached any fiduciary duty
to the Company, which breach is not cured within 30 days after written notice to such individual thereof; or (ii) engaged
in gross negligence, willful misconduct, willful violation of any law, fraud, embezzlement, material acts of dishonesty or a conflict
of interest that causes a Material Adverse Effect on the Company.

 

1.14         
“Certificate” has the meaning set forth in Section 3.2.

 

1.15         
“Claiming Party” has the meaning set forth in Section 10.7.1.

 

1.16         
“Closing” has the meaning set forth in Section 3.1.

 

1.17         
“Closing Acquiror Company Shares” means the aggregate number of Acquiror Shares issuable to the Shareholders
at Closing, less the Escrow Shares.

 

1.18         
“Closing Date” has the meaning set forth in Section 3.1.

 

1.19         
“Code” means the Internal Revenue Code of 1986, as amended.

 

     2

     

    

 

1.20         
“Common Stock” means the Company’s shares of Common Stock, without par value.

 

1.21         
“Commission” means the Securities and Exchange Commission or any other federal agency then administering
the Securities Act.

 

1.22         
“Company” has the meaning set forth in the recitals.

 

1.23         
“Company Board” means the Board of Directors of the Company.

 

1.24         
“Company Disclosure Schedules” has the meaning set forth in Section V.

 

1.25         
“Company Subsidiaries” means all of the direct and indirect Subsidiaries of the Company.

 

1.26         
“Deductible” has the meaning set forth in Section 10.4.

 

1.27         
“Director Nominee” means John Montgomery, subject to the completion and Acquiror Company Board acceptance,
which acceptance shall not be unreasonably withheld, of a standard third party background check and in the event Mr. Montgomery
fails such background check, an alternative representative to be appointed by the Company and to be approved by the Acquiror Company
Board, which approval shall not be unreasonably withheld.

 

1.28         
“Employment Agreements” has the meaning set forth in Section 2.5.

 

1.29         
“Environmental Laws” has the meaning set forth in Section 5.20.

 

1.30         
[Reserved].

 

1.31         
“Equity Security” means any stock or similar security, including, without limitation, securities containing
equity features and securities containing profit participation features, or any security convertible into or exchangeable for,
with or without consideration, any stock or similar security, or any security carrying any warrant, right or option to subscribe
to or purchase any shares of capital stock, or any such warrant or right.

 

1.32         
“Escrow Agent” has the meaning set forth in Section 3.2.

 

1.33         
“Escrow Period” has the meaning set forth in Section 10.6.

 

1.34         
“Escrow Shares” has the meaning set forth in Section 3.2.

 

1.35         
“Exchange Act” means the Securities Exchange Act of 1934 or any similar federal statute, and the rules
and regulations of the Commission thereunder, all as the same will then be in effect.

 

1.36         
“Exhibits” means the several exhibits referred to and identified in this Agreement.

 

1.37         
“FDA” has the meaning set forth in Section 5.24.

 

     3

     

    

 

1.38         
“FDCA” has the meaning set forth in Section 5.24.

 

1.39         
“Form 8-K” means a current report on Form 8-K under the Exchange Act.

 

1.40         
“GAAP” means, with respect to any Person, United States generally accepted accounting principles applied
on a consistent basis with such Person’s past practices.

 

1.41         
“Governmental Authority” means any federal or national, state or provincial, municipal or local government,
governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality,
political subdivision, commission, court, tribunal, official, arbitrator or arbitral body, in each case whether U.S. or non-U.S.

 

1.42         
“Hazardous Materials” has the meaning set forth in Section 5.20.

 

1.43         
“Indebtedness” means any obligation, contingent or otherwise. Any obligation secured by a Lien on, or
payable out of the proceeds of, or production from, property of the relevant party will be deemed to be Indebtedness.

 

1.44         
“Indemnification Cap” has the meaning set forth in Section 10.5.

 

1.45         
“Indemnification Notice” has the meaning set forth in Section 10.7.1.

 

1.46         
“Indemnification Notice Period” has the meaning set forth in Section 10.7.1.

 

1.47         
“Indemnifying Party” has the meaning set forth in Section 10.7.1.

 

1.48         
“Intellectual Property” means all industrial and intellectual property, including, without limitation,
all U.S. and non-U.S. patents, patent applications, patent rights, trademarks, trademark applications, common law trademarks, Internet
domain names, trade names, service marks, service mark applications, common law service marks, and the goodwill associated therewith,
copyrights, in both published and unpublished works, whether registered or unregistered, copyright applications, franchises, licenses,
know-how, trade secrets, technical data, designs, customer lists, confidential and proprietary information, processes and formulae,
all computer software programs or applications, layouts, inventions, development tools and all documentation and media constituting,
describing or relating to the above, including manuals, memoranda, and records, whether such intellectual property has been created,
applied for or obtained anywhere throughout the world.

 

1.49         
“Intellectual Property Rights” has the meaning set forth in Section 5.22.

 

1.50         
“knowledge of the Company” or “Company’s knowledge” means the actual or constructive
knowledge of the Company Board, or the Principals.

 

1.51         
“knowledge of the Acquiror Company” or “Acquiror Company’s knowledge” means
the actual or constructive knowledge of the Acquiror Company or the Acquiror Company Board.

 

     4

     

    

 

1.52         
“Laws” means, with respect to any Person, any U.S. or non-U.S. federal, national, state, provincial,
local, municipal, international, multinational or other law (including common law), constitution, statute, code, ordinance, rule,
regulation or treaty applicable to such Person.

 

1.53         
“Lien” means any mortgage, pledge, security interest, encumbrance, lien or charge of any kind, including,
without limitation, any conditional sale or other title retention agreement, any lease in the nature thereof and the filing of
or agreement to give any financing statement under the Uniform Commercial Code of any jurisdiction and including any lien or charge
arising by Law.

 

1.54         
“Lock-Up Period” has the meaning set forth in Section 4.4.

 

1.55         
“Losses” has the meaning set forth in Section 10.1.

 

1.56         
“Material Acquiror Company Contract” means any and all agreements, contracts, arrangements, leases, commitments
or otherwise, to which the Acquiror Company is a party or otherwise bound, that the Acquiror Company would be required to file
with the Commission upon their occurrence in accordance with U.S. securities laws.

 

1.57         
“Material Adverse Effect” means, when used with respect to either the Acquiror Company or the Acquired
Companies, as the case may be, any change, effect or circumstance which, individually or in the aggregate, would reasonably be
expected to (a) have a material adverse effect on the business, assets, financial condition or results of operations of the Acquiror
Company or the Acquired Companies, as the case may be, in each case taken as a whole or (b) materially impair the ability of the
Acquiror Company or the Acquired Companies, as the case may be, to perform their obligations under this Agreement, excluding any
change, effect or circumstance resulting from (i) the announcement, pendency or consummation of the transactions contemplated by
this Agreement, (ii) changes in the United States securities markets generally, or (iii) changes in general economic, currency
exchange rate, political or regulatory conditions in industries in which the Acquiror Company or the Acquired Companies, as the
case may be, operate or (c) result in litigation, claims, disputes or property loss in the future, and that would prohibit or otherwise
materially interfere with the ability of any party to this Agreement to perform any of its obligations under this Agreement in
any material respect.

 

1.58         
“Material Company Contract” means any and all agreements, contracts, arrangements, leases, commitments
or otherwise, to which the Company is a party or otherwise bound, that the Acquiror Company would be required to file with the
Commission upon their occurrence in accordance with U.S. securities laws.

 

1.59         
“Material Permits” has the meaning set forth in Section 5.21.

 

1.60         
“Money Laundering Laws” has the meaning set forth in Section 5.31.

 

1.61         
[Reserved].

 

1.62         
“Order” means any award, decision, injunction, judgment, order, ruling, subpoena, or verdict entered,
issued, made, or rendered by any Governmental Authority.

 

     5

     

    

 

1.63         
“Organizational Documents” means (a) the articles or certificate of incorporation and the by-laws or
code of regulations of a corporation; (b) the partnership agreement and any statement of partnership of a general partnership;
(c) the limited partnership agreement and the certificate of limited partnership of a limited partnership; (d) the articles or
certificate of formation and operating agreement of a limited liability company; (e) any other document performing a similar function
to the documents specified in clauses (a), (b), (c) and (d) adopted or filed in connection with the creation, formation or organization
of a Person; and (f) any and all amendments to any of the foregoing.

 

1.64         
“Permitted Liens” means (a) Liens for Taxes not yet payable or in respect of which the validity thereof
is being contested in good faith by appropriate proceedings and for the payment of which the relevant party has made adequate reserves;
(b) Liens in respect of pledges or deposits under workmen’s compensation laws or similar legislation, carriers, warehousemen,
mechanics, laborers and materialmen and similar Liens, if the obligations secured by such Liens are not then delinquent or are
being contested in good faith by appropriate proceedings conducted and for the payment of which the relevant party has made adequate
reserves; (c) statutory Liens incidental to the conduct of the business of the relevant party which were not incurred in connection
with the borrowing of money or the obtaining of advances or credits and that do not in the aggregate materially detract from the
value of its property or materially impair the use thereof in the operation of its business; and (d) Liens that would not have
a Material Adverse Effect.

 

1.65         
“Person” means all natural persons, corporations, business trusts, associations, companies, partnerships,
limited liability companies, joint ventures and other entities, governments, agencies and political subdivisions.

 

1.66         
“Pharmaceutical Product” has the meaning set forth in Section 5.24.

 

1.67         
“Proceeding” means any action, arbitration, audit, hearing, investigation, litigation, or suit (whether
civil, criminal, administrative or investigative) commenced, brought, conducted, or heard by or before, or otherwise involving,
any Governmental Authority.

 

1.68         
“Qualifying Shareholder” has the meaning set forth in Section 2.7.

 

1.69         
“Registrable Securities” means, as of any date of determination, (a) the Acquiror Company Shares and
(b) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event
with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities
(and the Acquiror Company shall not be required to maintain the effectiveness of any, or file another, registration statement hereunder
with respect thereto) for so long as (a) a registration statement with respect to the sale of such Registrable Securities is declared
effective by the Commission under the Securities Act and all such Registrable Securities have been disposed of by the Shareholder
in accordance with such effective registration statement, (b) such Registrable Securities have been previously sold in accordance
with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current
public information pursuant to Rule 144.

 

     6

     

    

 

1.70         
“Rule 144” means Rule 144 under the Securities Act, as the same may be amended from time to time, or
any successor statute.

 

1.71         
 “Schedules” means the several schedules referred to and identified herein, setting forth certain disclosures,
exceptions and other information, data and documents referred to at various places throughout this Agreement.

 

1.72         
“SEC Documents” has the meaning set forth in Section 6.15.

 

1.73         
“Section 4(2)” means Section 4(2) under the Securities Act, as the same may be amended from time to time,
or any successor statute.

 

1.74         
“Securities Act” means the Securities Act of 1933, as amended, or any similar federal statute, and the
rules and regulations of the Commission thereunder, all as the same will be in effect at the time.

 

1.75         
“Series A Preferred Stock” means the Acquiror Company’s Series A 0% convertible preferred stock,
par value $0.0001 per share, of which there are 1,748.625 shares at the Closing Date, with a stated value of $1,000 per share,
convertible at $0.53 per share into 3,299,294 shares of Acquiror Company Common Stock at the Closing Date, subject to adjustment.

 

1.76         
“Series B Preferred Stock” means the Acquiror Company’s Series B 0% convertible preferred stock,
par value $0.0001 per share, of which there are 961 shares at the Closing Date, with a stated value of $1,000 per share, convertible
at $0.53 per share into 1,813,210 shares of Acquiror Company Common Stock at the Closing Date, subject to adjustment.

 

1.77         
“Series C Preferred Stock” means the Acquiror Company’s Series A 0% convertible preferred stock,
par value $0.0001 per share, of which there are 290.43148 shares at the Closing Date, with a stated value of $1,000 per share,
convertible at $0.75 per share into 387,251 shares of Acquiror Company Common Stock at the Closing Date, subject to adjustment.

 

1.78         
“Share Escrow Agreement” means the escrow agreement substantially in the form of Exhibit A hereto,
pursuant to which the Principals shall deposit 973,251 of the Acquiror Company Shares to be received by the Principals into an
escrow account, which will serve as security for the partial indemnification against any breaches of this Agreement and the Transaction
Documents by the Company or the Principals, following the Share Exchange.

 

1.79         
“Share Exchange” has the meaning set forth in Section 2.1.

 

1.80         
“Shareholder Indemnified Persons” has the meaning set forth in Section 10.2.

 

1.81         
“Shareholders’ Representative” has the meaning set forth in the recitals.

 

1.82         
“Shareholders’ Representative Group” has the meaning set forth in Section 12.3.

 

1.83         
“Shares” means the issued and outstanding ordinary shares of the Company.

 

1.84         
[Reserved].

 

     7

     

    

 

1.85         
“Subsidiary” means, with respect to any Person, any corporation, limited liability company, joint venture
or partnership of which such Person (a) beneficially owns, either directly or indirectly, more than 50% of (i) the total combined
voting power of all classes of voting securities of such entity, (ii) the total combined equity interests, or (iii) the capital
or profit interests, in the case of a partnership or limited liability company; or (b) otherwise has the power to vote or to direct
the voting of sufficient securities to elect a majority of the board of directors or similar governing body.

 

1.86         
“Taxes” means all foreign, federal, state or local taxes, charges, fees, levies, imposts, duties and
other assessments, as applicable, including, but not limited to, any income, alternative minimum or add-on, estimated, gross income,
gross receipts, sales, use, transfer, transactions, intangibles, ad valorem, value-added, franchise, registration, title, license,
capital, paid-up capital, profits, withholding, payroll, employment, unemployment, excise, severance, stamp, occupation, premium,
real property, recording, personal property, federal highway use, commercial rent, environmental (including, but not limited to,
taxes under Section 59A of the Code) or windfall profit tax, custom, duty or other tax, governmental fee or other like assessment
or charge of any kind whatsoever, together with any interest, penalties or additions to tax with respect to any of the foregoing;
and “Tax” means any of the foregoing Taxes.

 

1.87         
 “Tax Return” means any return, declaration, report, claim for refund or credit, information return,
statement or other similar document filed with any Governmental Authority with respect to Taxes, including any schedule or attachment
thereto, and including any amendment thereof.

 

1.88         
“Third Party Claim” has the meaning set forth in Section 10.7.1.

 

1.89         
“Third Party Claim Notice” has the meaning set forth in Section 10.7.1.

 

1.90         
“Trading Day” means a day on which the principal Trading Market is open for trading.

 

1.91         
“Trading Market” means any of the following markets or exchanges on which the Acquiror Company’s
Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global
Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the
foregoing.

 

1.92         
“Transaction Documents” means, collectively, all agreements, instruments and other documents to be executed
and delivered in connection with the transactions contemplated by this Agreement including but not limited to, the Agreement, the
Share Escrow Agreement, and the Employment Agreements.

 

1.93         
“U.S.” means the United States of America.

 

1.94         
“U.S. Dollars” or “US $” means the currency of the United States of America.

 

     8

    

    

 

1.95         
“VWAP” means, for any date or applicable period in question, the price determined by the first of the
following clauses that applies: (a) if the Acquiror Company’s Common Stock is then listed or quoted on a Trading Market,
the daily volume weighted average price of the Acquiror Company’s Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Acquiror Company’s Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if the OTC Bulletin Board
is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on
the OTC Bulletin Board, (c) if the Acquiror Company’s Common Stock is not then listed or quoted for trading on the OTC Bulletin
Board and if prices for the Acquiror Company’s Common Stock are then reported in the “Pink Sheets” published
by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Acquiror
Company’s Common Stock as determined by the Acquiror Company Board.

 

SECTION
II

EXCHANGE OF SHARES AND SHARE CONSIDERATION

 

2.1             
Share Exchange. At the Closing, the Shareholders shall transfer 3,936,242 Shares, representing all of the issued
and outstanding shares of the Company, and, in consideration therefor, subject to Section 2.2, Acquiror Company shall issue
to Shareholders an aggregate of 7,122,172 fully paid and nonassessable shares of Acquiror Company Common Stock, representing 50%
of shares of the Acquiror Company’s Common Stock (assuming the conversion of all issued and outstanding Acquiror Company
Preferred Stock into shares of Acquiror Company Common Stock at the Closing Date) to be issued on the Closing Date (the “Share
Exchange”).

 

2.2              Withholding.
The Acquiror Company shall be entitled to deduct and withhold from the Acquiror Company Shares otherwise issuable pursuant to
this Agreement to any Shareholder such amounts as it is required to deduct and withhold with respect to the making of such payment
under the Code or any provision of state, local, provincial or foreign tax Law. To the extent that amounts are so withheld, such
withheld amounts shall be treated for all purposes of this Agreement as having been paid to such Shareholder in respect of which
such deduction and withholding was made.

 

2.3             
Section 368 Reorganization. For U.S. federal income tax purposes, the Share Exchange is intended to constitute a
“reorganization” within the meaning of Section 368(a)(1)(B) of the Code. The parties to this Agreement hereby adopt
this Agreement as a “plan of reorganization” within the meaning of Sections 1.368-2(g) and 1.368-3(a) of the United
States Treasury Regulations. Notwithstanding the foregoing or anything else to the contrary contained in this Agreement, the parties
acknowledge and agree that no party is making any representation or warranty as to the qualification of the Share Exchange as a
reorganization under Section 368 of the Code or as to the effect, if any, that any transaction consummated prior to the Closing
Date has or may have on any such reorganization status. The parties acknowledge and agree that each (i) has had the opportunity
to obtain independent legal and tax advice with respect to the transaction contemplated by this Agreement, and (ii) is responsible
for paying its own Taxes, including without limitation, any adverse Tax consequences that may result if the transaction contemplated
by this Agreement is not determined to qualify as a reorganization under Section 368 of the Code.

 

     9

    

    

 

2.4             
Directors of Acquiror Company at Closing Date. On the Closing Date, the Acquiror Company Board shall cause the Director
Nominee to become a member of the Acquiror Company Board, such Board membership to be subject to the provisions of Paragraph 1.27.
The Acquiror Company shall not remove, or cause or permit to be removed, the Director Nominee for a period of at least twelve (12)
months following his appointment without Cause.

 

2.5             
Employment Agreements. On the Closing Date, the Acquiror Company shall enter into a two-(2) year employment agreement
with each of Robert D. Thompson and Larry E. Rodman in substantially the same form as attached hereto as Exhibit B (“Employment
Agreements”).

 

2.6             
[Reserved].

 

2.7             
Voting Agreement. Upon the execution of this Agreement, (i) all officers of the Company, (ii) members of the Company
Board and (iii) individual Shareholders that will receive at least 5.0% of the voting power of the outstanding Acquiror Company
Shares (including shares held in escrow pursuant to the Share Escrow Agreement) (each, a “Qualifying Shareholder”),
agree to vote any and all Acquiror Company Shares received by such Qualifying Shareholder in the transaction contemplated hereby,
in accordance with the recommendation of the Acquiror Company Board with respect to any matter to be voted upon by the shareholders
of the Acquiror Company, for a period of eighteen (18) months from the Closing Date, except to the extent prohibited by Laws.

 

SECTION
III

CLOSING DATE

 

3.1             
Closing Date. The closing of the Share Exchange (the “Closing”) will occur on the date on which
all of the closing conditions set forth in Sections VIII and IX have been satisfied or waived (the “Closing
Date”), subject to extension by mutual agreement of the Company and the Acquiror Company, but in no event later than
July [*], 2017.

 

3.2             
Escrow. Notwithstanding any provision of this Agreement to the contrary, in lieu of delivering to the Principals
(each of which is also a Shareholder) certificates (or book-entry form confirmation) (“Certificate”) for the
full number of Acquiror Company Shares provided for in Section 2.1, the Acquiror Company shall deliver or cause to be delivered
(A) to each Principal, a Certificate registered in the name of such Principal evidencing such number of Closing Acquiror Company
Shares as set forth in Exhibit A and (B) to Silvestre Law Group, P.C., as escrow agent (the “Escrow Agent”)
for deposit into escrow pursuant to the Share Escrow Agreement, a Certificate in the name of each Principal evidencing such number
of Acquiror Company Shares to be deposited into such escrow as set forth in Exhibit A (all Acquiror Company Shares to be
deposited into such escrow, collectively, the “Escrow Shares”), together with a stock power endorsed in blank
for the shares represented on each such Certificate, which Certificate will be held in the escrow account and disposed of by the
Escrow Agent in accordance with the terms and provisions of the Share Escrow Agreement. All Escrow Shares will be deducted from
the Acquiror Company Shares (on a pro rata basis of the Principals’ relative ownership of the Shares).

 

     10

    

    

 

SECTION
IV

REPRESENTATIONS AND WARRANTIES OF SHAREHOLDERS

 

4.1               Generally. Each Shareholder, or Principal, as applicable below, severally and not jointly, hereby represents and
warrants to the Acquiror Company:

 

4.1.1               Authority. Such Shareholder has the right, power, authority and capacity to execute and deliver this Agreement and
each of the Transaction Documents to which such Shareholder is a party, to consummate the transactions contemplated by this Agreement
and each of the Transaction Documents to which such Shareholder is a party, and to perform such Shareholder’s obligations
under this Agreement and each of the Transaction Documents to which such Shareholder is a party, as applicable. This Agreement
has been, and each of the Transaction Documents to which such Shareholder is a party will be, duly and validly authorized and approved,
executed and delivered by such Shareholder. Assuming this Agreement and the Transaction Documents have been duly and validly authorized,
executed and delivered by the parties thereto other than such Shareholder, this Agreement is, and each of the Transaction Documents
to which such Shareholder is a party have been, duly authorized, executed and delivered by such Shareholder and constitutes the
legal, valid and binding obligation of such Shareholder, enforceable against such Shareholder in accordance with their respective
terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar Laws
affecting the enforcement of creditors rights generally.

 

4.1.2              
No Conflict. Neither the execution or delivery by such Shareholder of this Agreement or any Transaction Document
to which such Shareholder is a party, nor the consummation or performance by such Shareholder of the transactions contemplated
hereby or thereby will, directly or indirectly, (a) contravene, conflict with, or result in a violation of any provision of the
Organizational Documents of such Shareholder (if such Shareholder is not a natural person); (b) contravene, conflict with, constitute
a default (or an event or condition which, with notice or lapse of time or both, would constitute a default) under, or result in
the termination or acceleration of, any agreement or instrument to which such Shareholder is a party or by which the properties
or assets of such Shareholder are bound; or (c) contravene, conflict with, or result in a violation of, any Law or Order to which
such Shareholder, or any of the properties or assets of such Shareholder, may be subject.

 

4.1.3             
Ownership of Shares. Such Shareholder owns, of record and beneficially, and has good, valid and indefeasible title
to and the right to transfer to the Acquiror Company pursuant to this Agreement, such Shareholder’s Shares free and clear
of any and all Liens. There are no options, rights, voting trusts, stockholder agreements or any other contracts or understandings
to which such Shareholder is a party or by which such Shareholder or such Shareholder’s Shares are bound with respect to
the issuance, sale, transfer, voting or registration of such Shareholder’s Shares. At the Closing Date, the Acquiror Company
will acquire good, valid and marketable title to such Shareholder’s Shares free and clear of any and all Liens.

 

4.1.4             
Litigation. There is no pending Proceeding against such Shareholder that involves the Shares or that challenges,
or may have the effect of preventing, delaying or making illegal, or otherwise interfering with, any of the transactions contemplated
by this Agreement and, to the knowledge of such Shareholder, no such Proceeding has been threatened, and no event or circumstance
exists that is reasonably likely to give rise to or serve as a basis for the commencement of any such Proceeding.

 

     11

    

    

 

4.1.5           
  No Brokers or Finders. No Person has, or as a result of the transactions contemplated herein will have, any right
or valid claim against such Shareholder for any commission, fee or other compensation as a finder or broker, or in any similar
capacity, and such Shareholder will indemnify and hold the Acquiror Company harmless against any liability or expense arising out
of, or in connection with, any such claim.

 

4.2               Investment Representations. Each Shareholder, severally and not jointly, hereby represents and warrants to the Acquiror
Company:

 

4.2.1              Acknowledgment.
Such Shareholder understands and agrees that the Acquiror Company Shares to be issued pursuant to this Agreement and the Share
Exchange have not been registered under the Securities Act or the securities laws of any state of the U.S. and that the issuance
of the Acquiror Company Shares is being effected in reliance upon an exemption from registration afforded either under Section
4(2) of the Securities Act for transactions by an issuer not involving a public offering.

 

4.2.2             
Status. By its execution of this Agreement, such Shareholder, severally and not jointly, represents and warrants
to the Acquiror Company as indicated on its signature page to this Agreement that such Shareholder is an Accredited Investor and
further makes the representations and warranties to the Acquiror Company set forth on Exhibit D. Such Shareholder understands
that the Acquiror Company Shares are being offered and sold to such Shareholder in reliance upon the truth and accuracy of the
representations, warranties, agreements, acknowledgments and understandings of such Shareholder set forth in this Agreement, in
order that the Acquiror Company may determine the applicability and availability of the exemptions from registration of the Acquiror
Company Shares on which the Acquiror Company is relying.

 

4.2.3              
Stock Legends. Such Shareholder hereby agrees with the Acquiror Company as follows:

 

(a)               
Securities Act Legend Accredited Investors. The Certificate evidencing the Acquiror Company Shares issued to such
Shareholder will bear the following legend:

 

THIS SECURITY
HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE
501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES

 

     12

    

    

 

(b)               Other
Legends. The Certificates representing such Acquiror Company Shares, and each Certificate issued in transfer thereof, will
also bear any other legend required under any applicable Law, including, without limitation, any U.S. state corporate and state
securities law, or contract.

 

(c)               Opinion.
No Shareholder will transfer any or all of the Acquiror Company Shares absent an effective registration statement under the Securities
Act and applicable state securities law covering the disposition of such Shareholder’s Acquiror Company Shares, without
first providing the Acquiror Company with an opinion of counsel (which counsel and opinion are reasonably satisfactory to the
Acquiror Company and only if requested by the Acquiror Company) to the effect that such transfer will be exempt from the registration
and the prospectus delivery requirements of the Securities Act and the registration or qualification requirements of any applicable
U.S. state securities laws.

 

(d)              
Consent. Each Shareholder understands and acknowledges that the Acquiror Company may refuse to transfer the Acquiror
Company Shares, unless such Shareholder complies with this Section 4.2.3 and any other restrictions on transferability set forth
in Exhibit D. Each Shareholder consents to the Acquiror Company making a notation on its records or giving instructions
to any transfer agent of the Acquiror Company’s Common Stock in order to implement the restrictions on transfer of the Acquiror
Company Shares.

 

4.3              Voting
Agreement. Each Shareholder, severally and not jointly, hereby represents and warrants to the Acquiror Company that if it
qualifies as a Qualified Shareholder, it will vote any and all Acquiror Company Shares received, pursuant to Section 2.7
hereof.

 

4.4              Lock-Up.
Each Shareholder, severally and not jointly, hereby represents and warrants to the Acquiror Company that for a period of eighteen
(18) months following the Closing Date (the “Lock-Up Period”), it will not transfer, sell, contract to sell,
devise, gift, assign, pledge, hypothecate, distribute or grant any option to purchase or otherwise dispose of, directly or indirectly,
any of the Acquiror Company Shares received in the transaction contemplated hereby, except that if a Shareholder is employed by
the Acquiror Company from time to time, such Shareholder may sell, pursuant to all applicable securities laws, up to five percent
(5%) (based on the total amount of received on the Closing Date) of their Acquiror Company Shares on each ninety (90) day anniversary
following the one (1) year anniversary of the Closing Date. The Lock-Up Period shall not limit in any way the Acquiror Company’s
obligations set forth in Section XI.

 

     13

    

    

 

4.5              Potential
Forfeiture of Escrow Amount. Each Principal, severally and not
jointly, hereby represents and warrants to the Acquiror Company that in the event that the Company or Shareholders
breach the provisions this Agreement, including any breaches by the Company of the representations and warranties under
Section 5, then such Principal’s Acquiror Company Shares included in the Escrow Amount are subject to forfeiture in
order to cover any damages pursuant to the indemnification provisions contained in Section X hereof.

 

SECTION
V

REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND PRINCIPALS

 

The disclosure schedules
attached hereto as Exhibit E (the “Company and Principal Disclosure Schedules”) are divided into sections
that correspond to the sections of this Section V. The Company and Principal Disclosure Schedule comprises a list of all
exceptions to the truth and accuracy in all material respects of, and of all disclosures or descriptions required by, the representations
and warranties set forth in the sections of this Section V. The disclosures in any section of the Company Disclosure Schedules
shall qualify other sections in this Section V only to the extent it is reasonably inferable from a reading of the disclosure
that such disclosure is applicable to such other sections. Notwithstanding anything contained herein to the contrary in this Agreement,
any representation, warranty or covenant made by the Company and its Principals shall be deemed to have been made to the best of
its or their knowledge. The Company and Principals represent and warrant to the Acquiror Company as follows:

 

5.1          Organization
and Qualification.

 

5.1.1               The
Company is duly incorporated and validly existing under the laws of the Commonwealth of Virginia, has all requisite authority
and corporate power, governmental licenses, authorizations, consents and approvals to carry on its business as presently conducted
and as contemplated to be conducted, to own, hold and operate its properties and assets as now owned, held and operated by it,
to enter into this Agreement, to carry out the provisions hereof except where the failure to be so organized, existing and in
good standing or to have such authority or power will not, in the aggregate, have a Material Adverse Effect. The Company is duly
qualified to conduct business and is in good standing as a foreign corporation in each jurisdiction wherein the nature of its
activities or its properties owned or leased makes such qualification necessary, except where the failure to be so qualified will
not have a Material Adverse Effect. Set forth on Schedule 5.1 is a list of those jurisdictions in which the Company presently
conducts its business, owns, holds and operates its properties and assets.

 

5.2              Subsidiaries. Except as set forth on Schedule 5.2, the Company does not own directly or indirectly, any equity
or other ownership interest in any corporation, partnership, joint venture or other entity or enterprise.

 

5.3              Organizational Documents.

 

5.3.1              
 The copies of the Certificate of Incorporation and Bylaws of the Company, each adopted on October 12, 2012, respectively,
that have been delivered to the Acquiror Company prior to the execution of this Agreement are true and complete and have not been
amended or repealed. The Company is not in violation or breach of any of the provisions of its Organizational Documents.

 

     14

    

    

 

5.4              Authorization
and Validity of this Agreement. The Company has all requisite authority and corporate power, governmental licenses, authorizations,
consents and approvals to enter into this Agreement and each of the Transaction Documents to which the Company is a party, to
consummate the transactions contemplated by this Agreement and each of the Transaction Documents to which the Company is a party,
to perform its obligations under this Agreement and each of the Transaction Documents to which the Company is a party, and to
record the transfer of the Shares and the delivery of the new certificates representing the Shares registered in the name of the
Acquiror Company. The execution, delivery and performance by the Company of this Agreement and each of the Transaction Documents
to which the Company is a party have been duly authorized by all necessary corporate action and do not require from the Company
Board or the Shareholders any consent or approval that has not been validly and lawfully obtained. The execution, delivery and
performance by the Company of this Agreement and each of the Transaction Documents to which the Company is a party requires no
authorization, consent, approval, license, exemption of or filing or registration with any Governmental Authority.

 

5.5             
No Violation. Neither the execution nor the delivery by the Company of this Agreement or any Transaction Document
to which the Company is a party, nor the consummation or performance by the Company of the transactions contemplated hereby or
thereby will, directly or indirectly, (a) contravene, conflict with, or result in a violation of any provision of the Organizational
Documents of the Company; (b) contravene, conflict with, constitute a default (or an event or condition which, with notice or lapse
of time or both, would constitute a default) under, or result in the termination or acceleration of, or result in the imposition
or creation of any Lien under, any agreement or instrument to which the Company is a party or by which the properties or assets
of the Company are bound ; (c) contravene, conflict with, or result in a violation of, any Law or Order to which the Company, or
any of the properties or assets owned or used by the Company, may be subject; or (d) contravene, conflict with, or result in a
violation of, the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel,
terminate or modify, any licenses, permits, authorizations, approvals, franchises or other rights held by the Company or that otherwise
relate to the business of, or any of the properties or assets owned or used by, the Company, except, in the case of clause (b),
(c), or (d), for any such contraventions, conflicts, violations, or other occurrences as would not have a Material Adverse Effect.

 

5.6             
Binding Obligations. Assuming this Agreement and the Transaction Documents have been duly and validly authorized,
executed and delivered by the parties thereto other than the Company, this Agreement and each of the Transaction Documents to which
the Company is a party are duly authorized, executed and delivered by the Company and constitute the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their respective terms, except as such enforcement is limited
by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights
generally.

 

     15

    

    

 

5.7             
Capitalization and Related Matters.

 

5.7.1             
Capitalization of the Company. The authorized capital stock of the Company consists of 5,000,000 shares of Common
Stock, of which 3,936,242 shares of Common Stock are issued and outstanding. Except as set forth on Schedule 5.7.1, there
are no outstanding or authorized options, warrants, calls, purchase agreements, participation agreements, subscription rights,
conversion rights, exchange rights or other securities or contracts that could require the Company to issue, sell or otherwise
cause to become outstanding any of its authorized but unissued shares of capital stock or any securities convertible into, exchangeable
for or carrying a right or option to purchase shares of capital stock or to create, authorize, issue, sell or otherwise cause to
become outstanding any new class of capital stock. There are no outstanding stockholders’ agreements, voting trusts or arrangements,
registration rights agreements, rights of first refusal or other contracts pertaining to the capital stock of the Company. The
issuance of all of the shares of Company’s Common Stock described in this Section 5.7.1 have been in compliance with
applicable federal and state Laws. All issued and outstanding shares of the Company’s capital stock are duly authorized,
validly issued, fully paid and nonassessable and have not been issued in violation of any preemptive or similar rights.

 

5.7.2             
No Redemption Requirements. There are no outstanding contractual obligations (contingent or otherwise) of the Company
to retire, repurchase, redeem or otherwise acquire any outstanding shares of capital stock of, or other ownership interests in,
the Company or to provide funds to or make any investment (in the form of a loan, capital contribution or otherwise) in any other
Person.

 

5.8              Shareholders.
Exhibit A contains a true and complete list of the names and addresses of the record and beneficial holders of all of the
outstanding capital stock of the Company. Except as expressly provided in this Agreement, no holder of Shares or any other security
of the Company is entitled to any preemptive right, right of first refusal or similar right with respect to the shares of the
Company’s capital stock.

 

5.9           
 Compliance with Laws and Other Instruments. Except as would not have a Material Adverse Effect, the business and
operations of the Company is being conducted in accordance with all applicable Laws and Orders. Except as would not have a Material
Adverse Effect, since January 1, 2014, the Company has not received notice of any violation (or any Proceeding involving an allegation
of any violation) of any applicable Law or Order by the Company, and to the knowledge of the Company, no Proceeding involving an
allegation of violation of any applicable Law or Order is threatened or contemplated. Except as would not have a Material Adverse
Effect, the Company is not alleged to be in violation of, or (with or without notice or lapse of time or both) in default under,
or in breach of, any term or provision of its Organizational Documents or of any indenture, loan or credit agreement, note, deed
of trust, mortgage, security agreement or other material agreement, lease, license or other instrument, commitment, obligation
or arrangement to which the Company is a party or by which any of the Company’s properties, assets or rights are bound. To
the knowledge of the Company, no other party to any material contract, agreement, lease, license, commitment, instrument or other
obligation to which the Company is a party is (with or without notice or lapse of time or both) in default thereunder or in breach
of any term thereof. Except in the ordinary course of business, the Company is not subject to any obligation or restriction of
any kind or character, nor is there, to the knowledge of the Company, any event or circumstance relating to the Company that materially
and adversely affects in any way its business, properties, assets or prospects or that prohibits the Company from entering into
this Agreement or would prevent or make burdensome its performance of or compliance with all or any part of this Agreement or the
consummation of the transactions contemplated hereby or thereby.

 

     16

    

    

 

5.10       Certain
Proceedings. There is no pending, or to the Company’s knowledge, threatened, Proceeding that has been commenced against
the Company and that challenges, or may have the effect of preventing, delaying, making illegal, or otherwise interfering with,
any of the transactions contemplated in this Agreement.

 

5.11       No
Brokers or Finders. Except as disclosed in Schedule 5.11, no person has, or as a result of the transactions contemplated
herein will have, any right or valid claim against the Company for any commission, fee or other compensation as a finder or broker,
or in any similar capacity, and the Company will indemnify and hold the Acquiror Company harmless against any liability or expense
arising out of, or in connection with, any such claim, in accordance with the indemnification provisions hereunder.

 

5.12       Title
to and Condition of Properties. Except as would not have a Material Adverse Effect, the Company
owns (with good and marketable title in the case of real property) or holds under valid leases or other rights to use all real
property, plants, machinery and equipment necessary for the conduct of the business of the Company as presently conducted, free
and clear of all Liens, except Permitted Liens. The material buildings, plants, machinery and equipment necessary for the conduct
of the business of the Company as presently conducted are structurally sound, are in good operating condition and repair and are
adequate for the uses to which they are being put, in each case, taken as a whole, and none of such buildings, plants, machinery
or equipment is in need of maintenance or repairs, except for ordinary, routine maintenance and repairs that are not material
in nature or cost.

 

5.13       [reserved.]

 

5.14       [reserved.]

 

5.15       Board
Recommendation. The Company Board has duly approved this Agreement and the transactions contemplated by this Agreement and
declared that this Agreement and the transactions contemplated by this Agreement, are advisable and in the best interests of the
Company and its Shareholders.

 

5.16       Changes.
Except as set forth in Schedule 5.16, since December 31, 2016, the Company has conducted its business in the usual and
ordinary course of business consistent with past practice and has not:

 

5.16.1       Adverse
Changes. Suffered or experienced any change in, or affecting, its condition (financial or otherwise), properties, assets,
liabilities, business, operations or prospects other than changes, events or conditions in the ordinary course of its business,
none of which would have a Material Adverse Effect;

 

5.16.2       Loans.
Made any loans or advances to any Person other than travel advances and reimbursement of expenses made to employees, officers
and directors in the ordinary course of business;

 

5.16.3       Liens.
Created or permitted to exist any Lien on any material property or asset of the Company, other than Permitted Liens;

 

     17

     

    

 

5.16.4       Capital
Stock. Issued, sold, disposed of or encumbered, or authorized the issuance, sale, disposition or encumbrance of, or granted
or issued any option to acquire any shares of its capital stock or any other Equity Security, or altered the term of any of its
outstanding securities or made any change in its outstanding shares of capital stock or its capitalization, whether by reason
of reclassification, recapitalization, stock split, combination, exchange or readjustment of shares, stock dividend or otherwise;

 

5.16.5       Dividends.
Declared, set aside, made or paid any dividend or other distribution to any of its stockholders;

 

5.16.6       Material
Company Contracts. Terminated or modified any Material Company Contract, except for termination upon expiration in accordance
with the terms thereof;

 

5.16.7       Claims.
Released, waived or cancelled any claims or rights relating to or affecting the Company in excess of US $50,000 in the aggregate
or instituted or settled any Proceeding involving in excess of US $50,000 in the aggregate;

 

5.16.8       Discharged
Liabilities. Paid, discharged or satisfied any claim, obligation or liability in excess of US $50,000 in the aggregate, except
for liabilities incurred prior to the date of this Agreement in the ordinary course of business;

 

5.16.9       Indebtedness.
Created, incurred, assumed or otherwise become liable for any Indebtedness in excess of US $50,000 in the aggregate, other than
professional fees;

 

5.16.10     Guarantees.
Guaranteed or endorsed any obligation or net worth of any Person exceeding $50,000 in the aggregate;

 

5.16.11     Acquisitions.
Acquired the capital stock or other securities or any ownership interest in, or substantially all of the assets of, any other
Person;

 

5.16.12     Accounting.
Changed its method of accounting or the accounting principles or practices utilized in the preparation of its financial statements,
other than as required by GAAP; or

 

5.16.13     Agreements.
Entered into any agreement, or otherwise obligated itself, to do any of the foregoing.

 

5.17       Litigation.
Except as set forth on Schedule 5.17, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against the Company, any of its Subsidiaries or any of their respective
properties before or by any Governmental Authority (collectively, an “Action”) which (i) adversely affects
or challenges the legality, validity or enforceability of this Agreement or any of the Transaction Documents to which the Company
is a party or (ii) could reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries,
nor, to the knowledge of the Company, any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There is no pending,
or to the knowledge of the Company, threatened, investigation by the Commission involving the Company or any current or former
director or officer of the Company.

 

     18

     

    

 

5.18       Labor
Relations. No labor dispute exists or, to the knowledge of the Company, is threatened with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company
and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement
or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment
and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance
could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

5.19       Compliance.
Neither the Company, nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has
the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.

 

5.20       Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to
pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or
subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses,
notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental
Laws”); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license
or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually
or in the aggregate, a Material Adverse Effect.

 

     19

     

    

 

5.21       Regulatory
Permits. The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses, as presently conducted, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any written notice of proceedings relating to the
revocation or modification of any Material Permit.

 

5.22       Intellectual
Property. The Company and its Subsidiaries have, or have rights to use, all Intellectual Property as necessary or required
for use in connection with their respective businesses and which the failure to so have could have a Material Adverse Effect (collectively,
the “Intellectual Property Rights”). Neither the Company nor any of its Subsidiaries has received a written
notice that any of the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate
or be abandoned, within five (5) years from the date of this Agreement, except where such occurrence could not reasonably be expected
to result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received a written notice of a claim
or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except
as could not have or reasonably be expected to not have a Material Adverse Effect. To the Company’s knowledge, all such
Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

 

5.23       Transactions
With Affiliates and Employees. Except as set forth in Schedule 5.23, none of the officers or directors of the Company
or any of its Subsidiaries and, to the Company’s Knowledge, none of the employees of the Company or any of its Subsidiaries,
is presently a party to any transaction with the Company or any of its Subsidiaries (other than for services as employees, officers
and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise
requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which
any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member
or partner, other than for: (i) payment of salary or consulting fees or similar payments for services rendered, (ii) reimbursement
for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements, restricted
stock awards or related agreements under any equity-based compensation plan of the Company.

 

     20

     

    

 

5.24       FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical
Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending or, to the Company’s knowledge,
threatened, Action against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
any written notice from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling
and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or
withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)
imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any
facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction
with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the
Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect.
The properties, business and operations of the Company have been and are being conducted in all material respects in accordance
with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit
the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the
Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed
to be developed by the Company. A list of all current Pharmaceutical Products and all applications with the FDA and FDCA, including
all current or contemplated trials, preclinical and clinical studies are set forth in Schedule 5.24 hereto.

 

5.25       Absence
of Undisclosed Liabilities. Except as set forth on Schedule 5.25 or any financial statements of the Company, as of
the date hereof, the Company has no debt, obligation or liability (whether accrued, absolute, contingent, liquidated or otherwise,
whether due or to become due) arising out of any transaction entered into at or prior to the Closing Date or any act or omission
at or prior to the Closing Date. Except as set forth on Schedule 5.25, as of the date hereof, the Company has not incurred
liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent
or otherwise).

 

5.26       Material
Company Contracts. The Company has provided to the Acquiror Company, prior to the date of this Agreement, true, correct and
complete copies of each written Material Company Contract, including each amendment, supplement and modification thereto.

 

5.27       No
Defaults. Each Material Company Contract is a valid and binding agreement of the Company, and is in full force and effect.
The Company is not in breach or default of any Material Company Contract to which it is a party and, to the Company’s Knowledge,
no other party to any Material Company Contract is in breach or default thereof. No event has occurred or circumstance exists
that (with or without notice or lapse of time) would (a) contravene, conflict with or result in a violation or breach of, or become
a default or event of default under, any provision of any Material Company Contract or (b) permit the Company or any other Person
the right to declare a default or exercise any remedy under, or to accelerate the maturity or performance of, or to cancel, terminate
or modify any Material Company Contract. The Company has not received written notice of the pending or threatened cancellation,
revocation or termination of any Material Company Contract to which it is a party. There are no renegotiations of, or attempts
to renegotiate, or outstanding rights to renegotiate any material terms of any Material Company Contract.

 

     21

     

    

 

5.28       Employees.
Except as would not have a Material Adverse Effect, the Company is in full compliance with all Laws regarding employment, wages,
hours, benefits, equal opportunity, collective bargaining, the payment of Social Security and other taxes, and occupational safety
and health. The Company is not liable for the payment of any compensation, damages, taxes, fines, penalties or other amounts,
however designated, for failure to comply with any of the foregoing Laws.

 

5.29       Tax
Returns and Audits.

 

5.29.1       Tax
Returns. Since January 1, 2012, the Company has filed all material Tax Returns required to be filed (if any) by or on behalf
of the Company and has paid all material Taxes of the Company required to have been paid (whether or not reflected on any Tax
Return). Except as set forth on Schedule 5.29, (a) since January 1, 2012, no Governmental Authority in any jurisdiction
has made a claim, assertion or threat to the Company that the Company is or may be subject to taxation by such jurisdiction; (b)
there are no Liens with respect to Taxes on the Company’s property or assets other than Permitted Liens; and (c) there are
no Tax rulings, requests for rulings, or closing agreements relating to the Company for any period (or portion of a period) that
would affect any period after the date hereof.

 

5.29.2       No
Adjustments, Changes. Neither the Company nor any other Person on behalf of the Company (a) has executed or entered into a
closing agreement pursuant to Section 7121 of the Code or any predecessor provision thereof or any similar provision of state,
local or foreign law; or (b) has agreed to or is required to make any adjustments pursuant to Section 481(a) of the Code or any
similar provision of state, local or foreign law.

 

5.29.3       No
Disputes. The Company has delivered to the Company true, correct and complete copies of all federal Tax Returns and examination
reports and statements of deficiencies assessed or asserted against or agreed to by the Company, if any, for each of the last
two (2) years and any and all correspondence with respect to the foregoing. There is no pending audit, examination, investigation,
dispute, proceeding or claim with respect to any Taxes of the Company, nor to the Company’s knowledge, is any such claim
or dispute threatened. The Company has not received written notice of any such audit, examination, investigation, dispute, proceeding
or claim with respect to any Taxes with respect to any periods.

 

5.29.4       Not
a U.S. Real Property Holding Corporation. The Company is not and has not been a United States real property holding corporation
within the meaning of Section 897(c)(2) of the Code at any time during the applicable period specified in Section 897(c)(1)(A)(ii)
of the Code.

 

5.29.5       No
Tax Allocation, Sharing. The Company is not and has not been a party to any Tax allocation or sharing agreement.

 

     22

     

    

 

5.29.6       No
Other Arrangements. The Company is not a party to any agreement, contract or arrangement for services that would result, individually
or in the aggregate, in the payment of any amount that would not be deductible by reason of Section 162(m), 280G or 404 of the
Code. The Company is not a “consenting corporation” within the meaning of Section 341(f) of the Code. The Company
does not have any “tax-exempt bond financed property” or “tax-exempt use property” within the meaning
of Section 168(g) or (h), respectively of the Code. The Company does not have any outstanding closing agreement, ruling request,
request for consent to change a method of accounting, subpoena or request for information to or from a Governmental Authority
in connection with any Tax matter. During the last two years, the Company has not engaged in any exchange with a related party
(within the meaning of Section 1031(f) of the Code) under which gain realized was not recognized by reason of Section 1031 of
the Code. The Company is not a party to any reportable transaction within the meaning of Treasury Regulation Section 1.6011-4.

 

5.30       Bank
Accounts and Safe Deposit Boxes. Schedule 5.30 discloses the title and number of each bank or other deposit or financial
account, and each lock box and safety deposit box currently used by the Company, the financial institution at which that account
or box is maintained and the names of the persons authorized to draw against the account or otherwise have access to the account
or box, as the case may be. To the Company’s knowledge, other than the bank accounts and safe deposit boxes referenced above
and included in Schedule 5.30, no other bank account or safe deposit box of the Company exists.

 

5.31       Money
Laundering Laws. The operations of the Company is and has been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all U.S. and non-U.S. jurisdictions, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any Governmental Authority (collectively, the “Money Laundering
Laws”) and no Proceeding involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company, threatened.

 

5.32       Adverse
Interest. Except as set forth on Schedule 5.32, no current officer, director, affiliate or person known to the Company
to be the record or beneficial owner in excess of 5% of the Common Stock or any person known to be an associate of any of the
foregoing is a party adverse to Company or has a material interest adverse to the Company in any material pending Proceeding.

 

5.33       No
“Bad Actor” Disqualification. The Company has exercised reasonable care to determine whether any Covered Person
(as defined below) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (“Disqualification Events”). To the Company’s knowledge, no Covered Person is
subject to a Disqualification Event, except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities
Act. The Company has complied, to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities
Act. “Covered Persons” are those persons specified in Rule 506(d)(1) under the Securities Act, including the
Company; any predecessor or affiliate of the Company; any director or executive officer; and any beneficial owner of 20% or more
of the Company’s outstanding voting equity securities, calculated on the basis of voting power.

 

     23

     

    

 

5.34       Untrue
Statements. Neither this Agreement nor the Schedules hereto nor any other documents, certificates or instruments furnished
to the Acquiror Company by or on behalf of Company or Shareholders in connection with the transactions contemplated by this Agreement
contain any untrue statement of a material fact or, to the Company’s knowledge, omit to state a material fact necessary
in order to make the statements made herein or therein, in the light of the circumstances under which they were made herein or
therein, not misleading.

 

5.35       No
Other Representations and Warranties; Delivery Via Upload to Dataroom. Except for the representations and warranties contained
in this Agreement, neither the Company nor the Shareholders makes any representation or warranty, express or implied, as to the
accuracy or completeness of any information regarding the Company or the business of the Company (including any representation
or warranty of any kind or nature whatsoever concerning or as to the accuracy or completeness of any projections, budgets, forecasts
or other forward-looking financial information concerning the future revenue, income, profit or other financial results of the
Company), in each case except as expressly set forth in this Agreement. The Company’s obligation to make available any agreement,
document or information to any Person under this Agreement shall have been satisfied if such agreement, document or information
has been uploaded in an electronic data room to which such Person has access.

 

SECTION
VI

REPRESENTATIONS AND WARRANTIES OF THE ACQUIROR COMPANY 

 

The
disclosure schedules attached hereto as Exhibit F (the “Acquiror Company Disclosure Schedules”) are
divided into sections that correspond to the sections of this Section VI. The Acquiror Company Disclosure Schedules comprise
a list of all exceptions to the truth and accuracy in all material respects of, and of all disclosures or descriptions required
by, the representations and warranties set forth in the remaining sections of this Section VI. The disclosures in any section
of the Acquiror Company Disclosure Schedules shall qualify other sections in this Section VI only to the extent it is reasonably
inferable from a reading of the disclosure that such disclosure is applicable to such other sections. For purposes of this Section
VI, any statement, facts, representations, or admissions contained in the public filings made by the Acquiror Company with
the Commissions, are deemed to be included in the Acquiror Company Disclosure Schedules and all such information is deemed to
be fully disclosed to the Company and the Shareholders. Notwithstanding anything contained herein to the contrary in this Agreement,
any representation, warranty or covenant made by the Acquiror Company shall be deemed to have been made to the best of their knowledge
for any period prior to January 1, 2013. For purposes of this Agreement, “to the best of our knowledge” or similar
phrase shall mean the actual or constructive knowledge of the Acquiror Company, the Acquiror Company Board, or its officers. The
Acquiror Company represents and warrants to the Shareholders and the Company as follows:

 

6.1         Organization
and Qualification. The Acquiror Company is duly incorporated under the laws of the state of Delaware, has all requisite authority
and corporate power, governmental licenses, authorizations, consents and approvals to carry on its business as presently conducted
and as contemplated to be conducted, to own, hold and operate its properties and assets as now owned, held and operated by it,
to enter into this Agreement, to carry out the provisions hereof except where the failure to be so organized, existing or to have
such authority or power will not, in the aggregate, have a Material Adverse Effect. The Acquiror Company is duly qualified to
conduct business as a foreign corporation in each jurisdiction wherein the nature of its activities or its properties owned or
leased makes such qualification necessary, except where the failure to be so qualified will not have a Material Adverse Effect.

 

     24

     

    

 

6.2       Subsidiaries.
Except as set forth on Schedule 6.2, the Acquiror Company does not own, directly or indirectly, any equity or other ownership
interest in any corporation, partnership, joint venture or other entity or enterprise.

 

6.3       Organizational
Documents. True, correct and complete copies of the Organizational Documents of the Acquiror Company have been delivered to
the Company prior to the execution of this Agreement, and no action has been taken to amend or repeal such Organizational Documents
since such date of delivery. The Acquiror Company is not in violation or breach of any of the provisions of its Organizational
Documents.

 

6.4       Authorization.
The Acquiror Company has all requisite authority and corporate power, governmental licenses, authorizations, consents and approvals
to enter into this Agreement and each of the Transaction Documents to which the Acquiror Company is a party, to consummate the
transactions contemplated by this Agreement and each of the Transaction Documents to which the Acquiror Company is a party and
to perform its obligations under this Agreement and each of the Transaction Documents to which the Acquiror Company is a party.
The execution, delivery and performance by the Acquiror Company of this Agreement and each of the Transaction Documents to which
the Acquiror Company is a party have been duly authorized by all necessary corporate action and do not require from the Acquiror
Company Board any consent or approval that has not been validly and lawfully obtained except for approval by the Acquiror Company
stockholders. The execution, delivery and performance by the Acquiror Company of this Agreement and each of the Transaction Documents
to which the Acquiror Company is a party requires no authorization, consent, approval, license, exemption of or filing or registration
with any Governmental Authority other than such other customary filings with the Commission for transactions of the type contemplated
by this Agreement and the Transaction Documents.

 

6.5         No
Violation. Neither the execution nor the delivery by the Acquiror Company of this Agreement or any Transaction Document to
which the Acquiror Company is a party, nor the consummation or performance by the Acquiror Company of the transactions contemplated
hereby or thereby will, directly or indirectly, (a) contravene, conflict with, or result in a violation of any provision of the
Organizational Documents of the Acquiror Company (b) contravene, conflict with, constitute a default (or an event or condition
which, with notice or lapse of time or both, would constitute a default) under, or result in the termination or acceleration of,
or result in the imposition or creation of any Lien under, any agreement or instrument to which the Acquiror Company is a party
or by which the properties or assets of the Acquiror Company is bound; (c) contravene, conflict with, or result in a violation
of, any Law or Order to which the Acquiror Company, or any of the properties or assets owned or used by the Acquiror Company,
may be subject; or (d) contravene, conflict with, or result in a violation of, the terms or requirements of, or give any Governmental
Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any licenses, permits, authorizations, approvals,
franchises or other rights held by the Acquiror Company or that otherwise relate to the business of, or any of the properties
or assets owned or used by, the Acquiror Company, except, in the case of clause (b), (c), or (d), for any such contraventions,
conflicts, violations, or other occurrences as would not have a Material Adverse Effect.

 

     25

     

    

 

6.6             
Binding Obligations. Assuming this Agreement and the Transaction Documents have been duly and validly authorized,
executed and delivered by the parties thereto other than the Acquiror Company, this Agreement and each of the Transaction Documents
to which the Acquiror Company is a party are duly authorized, executed and delivered by the Acquiror Company and constitutes the
legal, valid and binding obligations of the Acquiror Company, enforceable against the Acquiror Company in accordance with their
respective terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other
similar Laws affecting the enforcement of creditors rights generally.

 

6.7             
Securities Laws. Assuming the accuracy of the representations and warranties of the Shareholders, contained in Section
4.1 and Exhibit D, the issuance of the Acquiror Company Shares pursuant to this Agreement will be when issued and paid
for in accordance with the terms of this Agreement issued in accordance with exemptions from the registration and prospectus delivery
requirements of the Securities Act and the registration permit or qualification requirements of all applicable state securities
laws.

 

6.8             
Capitalization and Related Matters.

 

6.8.1                   
Capitalization. The authorized capital stock of the Acquiror Company consists of 180,000,000 shares: 150,000,000
shares of the Acquiror Company’s Common Stock are authorized, of which 1,622,417 shares are issued and outstanding; 30,000,000
shares of the Acquiror Company’s Preferred Stock are authorized, of which 1,815,249.056 shares are issued and outstanding.
All issued and outstanding shares of the Acquiror Company’s Common Stock and Acquiror Company’s Preferred Stock are
duly authorized, validly issued, fully paid and nonassessable, and have not been issued in violation of any preemptive or similar
rights. The Acquiror Company’s Preferred Stock is not entitled to any liquidation preference or right relating to anti-dilution,
voting (including right of veto) or dividend of any kind, except to the extent the Acquiror Company’s Common Stock is similarly
entitled to any such right. None of the transactions contemplated by this Agreement or any other Transaction Document shall trigger
any anti-dilution right of the Acquiror Company’s Preferred Stock. At the Closing Date, the Acquiror Company will have sufficient
authorized and unissued Acquiror Company’s Common Stock to consummate the transactions contemplated hereby.

 

6.8.2                 
Duly Authorized. The issuance of the Acquiror Company Shares has been duly authorized and, upon consummation of the
Closing, the Acquiror Company Shares will have been validly issued and fully paid, and will be nonassessable, have the rights,
preferences and privileges specified, will be free of preemptive rights and will be free and clear of all Liens and restrictions,
other than Liens created by the Shareholders and restrictions on transfer imposed by this Agreement and the Securities Act.

 

6.9              
Compliance with Laws. Since January 1, 2013 and, to the best of the Acquiror Company’s knowledge, for all periods
prior thereto, (i) the business and operations of the Acquiror Company have been and are being conducted in accordance with all
applicable Laws and Orders; and (ii) the Acquiror Company has not received notice of any violation (or any Proceeding involving
an allegation of any violation) of any applicable Law or Order by or affecting the Acquiror Company and no Proceeding involving
an allegation of violation of any applicable Law or Order is threatened or contemplated. The Acquiror Company is not subject to
any obligation or restriction of any kind or character, nor is there, to the knowledge of the Acquiror Company, any event or circumstance
relating to the Acquiror Company that materially and adversely affects in any way its business, properties, assets or prospects
or that prohibits the Acquiror Company from entering into this Agreement or would prevent or make burdensome its performance of
or compliance with all or any part of this Agreement or the consummation of the transactions contemplated hereby.

 

     26

     

    

 

6.10          
Certain Proceedings. There is no pending, or to the Acquiror Company’s knowledge, threatened, Proceeding that
has been commenced against the Acquiror Company and that challenges, or may have the effect of preventing, delaying, making illegal,
or otherwise interfering with, any of the transactions contemplated by this Agreement.

 

6.11          
No Brokers or Finders. Except as disclosed in Schedule 6.11, no Person has, or as a result of the transactions
contemplated herein will have, any right or valid claim against the Acquiror Company for any commission, fee or other compensation
as a finder or broker, or in any similar capacity, and the Acquiror Company will indemnify and hold the Shareholders harmless against
any liability or expense arising out of, or in connection with, any such claim, in accordance with the indemnification provisions
hereunder.

 

6.12          
Absence of Undisclosed Liabilities. Except as set forth on Schedule 6.12 or in the SEC Documents, as of the
date hereof, the Acquiror Company has no debt, obligation or liability (whether accrued, absolute, contingent, liquidated or otherwise,
whether due or to become due) arising out of any transaction entered into at or prior to the Closing Date or any act or omission
at or prior to the Closing Date. Except as set forth on Schedule 6.12 or in the SEC Documents, as of the date hereof, the
Acquiror Company has not incurred liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured,
absolute, accrued, contingent or otherwise).

 

6.13          
Changes. Except as set forth in the SEC Documents or in Schedule 6.13, the Acquiror Company has, conducted
its business in the usual and ordinary course of business consistent with past practice and has not:

 

6.13.1               
Adverse Changes. Suffered or experienced any change in, or affecting, its condition (financial or otherwise), properties,
assets, liabilities, business, operations, results of operations or prospects other than changes, events or conditions in the usual
and ordinary course of its business, none of which would have a Material Adverse Effect;

 

6.13.2               
Loans. Made any loans or advances to any Person other than travel advances and reimbursement of expenses made to
employees, officers and directors in the ordinary course of business;

 

6.13.3               
Liens. Created or permitted to exist any Lien on any material property or asset of the Acquiror Company, other than
Permitted Liens;

 

6.13.4               
Capital Stock. Issued, sold, disposed of or encumbered, or authorized the issuance, sale, disposition or encumbrance
of, or granted or issued any option to acquire any shares of its capital stock or any other Equity Security, or altered the term
of any of its outstanding securities or made any change in its outstanding shares of capital stock or its capitalization, whether
by reason of reclassification, recapitalization, stock split, combination, exchange or readjustment of shares, stock dividend or
otherwise;

 

     27

     

    

 

6.13.5               
Dividends. Declared, set aside, made or paid any dividend or other distribution to any of its stockholders;

 

6.13.6              
Material Acquiror Company Contracts. Terminated or modified any Material Acquiror Company Contract, except for termination
upon expiration in accordance with the terms thereof;

 

6.13.7               
Claims. Released, waived or cancelled any claims or rights relating to or affecting the Acquiror Company in excess
of US $50,000 in the aggregate or instituted or settled any Proceeding involving in excess of US $50,000 in the aggregate;

 

6.13.8               
Discharged Liabilities. Paid, discharged or satisfied any claim, obligation or liability in excess of US $50,000
in the aggregate, except for liabilities incurred prior to the date of this Agreement in the ordinary course of business;

 

6.13.9               
Indebtedness. Created, incurred, assumed or otherwise become liable for any Indebtedness in excess of US $50,000
in the aggregate, other than professional fees;

 

6.13.10            
Guarantees. Guaranteed or endorsed any obligation or net worth of any Person exceeding $50,000 in the aggregate;

 

6.13.11           
Acquisitions. Acquired the capital stock or other securities or any ownership interest in, or substantially all of
the assets of, any other Person;

 

6.13.12           
Accounting. Changed its method of accounting or the accounting principles or practices utilized in the preparation
of its financial statements, other than as required by GAAP; or

 

6.13.13           
Agreements. Entered into any agreement, or otherwise obligated itself, to do any of the foregoing.

 

6.14         
 No Defaults. Each Material Acquiror Company Contract is a valid and binding agreement of the Acquiror Company, and
is in full force and effect. The Acquiror Company is not in breach or default of any Material Acquiror Company Contract to which
it is a party and, to the knowledge of the Acquiror Company, no other party to any Material Acquiror Company Contract is in breach
or default thereof. No event has occurred or circumstance exists that (with or without notice or lapse of time) would (a) contravene,
conflict with or result in a violation or breach of, or become a default or event of default under, any provision of any Material
Acquiror Company Contract or (b) permit the Acquiror Company or any other Person the right to declare a default or exercise any
remedy under, or to accelerate the maturity or performance of, or to cancel, terminate or modify any Material Acquiror Company
Contract. The Acquiror Company has not received written notice of the pending or threatened cancellation, revocation or termination
of any Material Acquiror Company Contract to which it is a party. There are no renegotiations of, or attempts to renegotiate, or
outstanding rights to renegotiate any material terms of any Material Acquiror Company Contract.

 

     28

     

    

 

6.15          
SEC Documents; Financial Statements. Except as set forth on Schedule 6.15, since January 1, 2011 and, to the
best of the Acquiror Company’s knowledge, for all periods prior thereto, the Acquiror Company has filed all reports required
to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the five (5) years preceding
the date hereof (or such shorter period as the Acquiror Company was required by law to file such material) (the foregoing materials
being collectively referred to herein as the “SEC Documents”). As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations
of the Commission promulgated thereunder, and none of the SEC Documents, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statement therein, in
light of the circumstances under which they were made, not misleading. All Material Acquiror Company Contracts to which the Acquiror
Company is a party or to which the property or assets of the Acquiror Company are subject have been appropriately filed as exhibits
to the SEC Documents as and to the extent required under the Exchange Act. The financial statements of the Acquiror Company included
in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the
Commission with respect thereto as in effect at the time of filing, were prepared in accordance with GAAP applied on a consistent
basis during the periods involved (except as may be indicated in the notes thereto, or, in the case of unaudited statements as
permitted by Form 10-Q, as the case may be, of the Commission), and fairly present in all material respects (subject in the case
of unaudited statements, to normal, recurring audit adjustments) the financial position of the Acquiror Company as at the dates
thereof and the results of its operations and cash flows for the periods then ended.

 

6.16           
[Reserved].

 

6.17          
Untrue Statements. Neither this Agreement nor the Schedules hereto nor any other documents, certificates or instruments
furnished to the Company or the Shareholder by or on behalf of Acquiror Company in connection with the transactions contemplated
by this Agreement contain any untrue statement of a material fact or, to the Acquiror Company’s knowledge, omit to state
a material fact necessary in order to make the statements made herein or therein, in the light of the circumstances under which
they were made herein or therein, not misleading.

 

6.18          
Board Recommendation. The Acquiror Company Board, by unanimous written consent, has determined that this Agreement
and the transactions contemplated by this Agreement are advisable and in the best interests of the Acquiror Company’s stockholders
and has duly authorized this Agreement and the transactions contemplated by this Agreement.

 

6.19          
No Suspension of Trading. The Acquiror Company has not been suspended from having its shares of capital stock trade
on securities exchanges, nor does the Acquiror Company have any knowledge of facts or events that could reasonably lead to such
suspension.

 

6.20   
        No “Bad Actor” Disqualification. The Acquiror Company
has exercised reasonable care to determine whether any Covered Person (as defined below) is subject to Disqualification
Event.  To the Acquiror Company’s knowledge, no Covered Person is subject to a Disqualification Event, except for
a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act.  The Acquiror Company has
complied, to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act.

 

     29

     

    

 

SECTION
VII

COVENANTS AND AGREEMENTS OF THE ACQUIROR COMPANY

 

7.1              
Form 8-K. Within four (4) business days of the Closing Date, the Acquiror Company shall file the Form 8-K disclosing
the transactions contemplated hereby in the Transaction Documents.

 

7.2             
Furnishing of Information; Public Information. At any time during the period commencing from the Closing Date and
ending twenty-four (24) months after the Closing Date, the Acquiror Company shall satisfy the current public information requirement
under Rule 144(c).

 

SECTION
VIII

CONDITIONS PRECEDENT OF THE ACQUIROR COMPANY

 

The Acquiror Company’s
obligation to acquire the Shares and to take the other actions required to be taken by the Acquiror Company at the Closing Date
is subject to the satisfaction, at or prior to the Closing Date, of each of the following conditions (any of which may be waived
by the Acquiror Company, in whole or in part):

 

8.1             
Accuracy of Representations. The representations and warranties of the Company, Principals and the Shareholders set
forth in this Agreement or in any Schedule or certificate delivered pursuant hereto shall be true and correct in all material respects
as of the date of this Agreement, except to the extent a representation or warranty is expressly limited by its terms to another
date and without giving effect to any supplemental Schedule (in which case such representation or warranty shall be true and correct
in all material respects as of such date) or a representation or warranty is qualified by its term by a reference to materiality
(in which case such representation or warranty shall be true and correct in all respects).

 

8.2              
Performance by the Company, Principals and Shareholders.

 

8.2.1                  All
of the covenants and obligations that the Company, Principals and the Shareholders are required to perform or to comply with pursuant
to this Agreement (considered collectively), and each of these covenants and obligations (considered individually), must have
been duly performed and complied with in all material respects.

 

8.2.2                  
Each document required to be delivered by the Company and the Shareholders pursuant to this Agreement must have been delivered.

 

8.3             
No Force Majeure Event. There shall not have been any delay, error, failure or interruption in the conduct of the
business of the Company, or any loss, injury, delay, damage, distress, or other casualty, due to force majeure including but not
limited to (a) acts of God; (b) fire or explosion; (c) war, acts of terrorism or other civil unrest; or (d) national emergency.

 

     30

     

    

 

8.4              
Certificate of Officer and Principals. The Company and Principals will have delivered to the Acquiror Company a certificate
executed by an officer of the Company on the Company’s behalf, and each Principal, on its own behalf, certifying the satisfaction
of the conditions specified in Sections 8.1 and 8.2, relating to the Company.

 

8.5             
Certificate of Shareholders. Each Shareholder will have delivered to the Acquiror Company a certificate executed
by such Shareholder, if a natural person, or an authorized officer of the Shareholder, if an entity, certifying the satisfaction
of the conditions specified in Sections 8.1 and 8.2 relating to such Shareholder.

 

8.6              
Consents.

 

8.6.1                  
All material consents, waivers, approvals, authorizations or orders required to be obtained, and all filings required to
be made, by the Company and/or the Shareholders for the authorization, execution and delivery of this Agreement and the consummation
by them of the transactions contemplated by this Agreement, shall have been obtained and made by the Company or the Shareholders,
as the case may be, except where the failure to receive such consents, waivers, approvals, authorizations or orders or to make
such filings would not have a Material Adverse Effect on the Company.

 

8.7             
Documents. The Company, Principals and the Shareholders must deliver to the Acquiror Company at the Closing:

 

8.7.1                  
[Reserved].

 

8.7.2                  
each of the Transaction Documents to which the Company, the Principals, the Shareholders and/or the Shareholders’
Representative is a party, duly executed;

 

8.7.3                  
 an officer’s certificate executed by an officer of the Company on the Company’s behalf, certifying the number
of issued and outstanding shares of the Company before and after the Closing; and,

 

8.7.4                 
such other documents as the Acquiror Company may reasonably request for the purpose of (A) evidencing the accuracy of any
of the representations and warranties of the Company, Principals and the Shareholders pursuant to Section 8.1, (B) evidencing
the performance of, or compliance by the Company and the Shareholders with, any covenant or obligation required to be performed
or complied with by the Company or the Shareholders, as the case may be, (C) evidencing the satisfaction of any condition referred
to in this Section 8.1, or (D) otherwise facilitating the consummation or performance of any of the transactions contemplated
by this Agreement.

 

8.8             
No Proceedings. There must not have been commenced or threatened against the Acquiror Company, the Company or any
Shareholder, or against any Affiliate thereof, any Proceeding (which Proceeding remains unresolved as of the Closing Date) (a)
involving any challenge to, or seeking damages or other relief in connection with, any of the transactions contemplated by this
Agreement, or (b) that may have the effect of preventing, delaying, making illegal, or otherwise interfering with any of the transactions
contemplated by this Agreement.

 

     31

     

    

 

8.9             
No Claim Regarding Stock Ownership or Consideration. There must not have been made or threatened by any Person, other
than persons listed on Schedule I hereto, any claim asserting that such Person (a) is the holder of, or has the right to
acquire or to obtain beneficial ownership of the Shares or any other stock, voting, equity, or ownership interest in, the Company,
or (b) is entitled to all or any portion of the Acquiror Company Shares.

 

SECTION
IX

CONDITIONS PRECEDENT OF THE COMPANY AND THE SHAREHOLDERS

 

The Shareholders’
obligation to transfer the Shares and the obligations of the Company or the Shareholders to take the other actions required to
be taken thereby in advance of or at the Closing Date are subject to the satisfaction, at or prior to the Closing Date, of each
of the following conditions (any of which may be waived by the Company and the Shareholders jointly, in whole or in part):

 

9.1             
Accuracy of Representations. The representations and warranties of the Acquiror Company set forth in this Agreement
or in any Schedule or certificate delivered pursuant hereto shall be true and correct in all material respects as of the date of
this Agreement, except to the extent a representation or warranty is expressly limited by its terms to another date and without
giving effect to any supplemental Schedule (in which case such representation or warranty shall be true and correct in all material
respects as of such date) or a representation or warranty is qualified by its term by a reference to materiality (in which case
such representation or warranty shall be true and correct in all respects).

 

9.2             
Performance by the Acquiror Company.

 

9.2.1                  
All of the covenants and obligations that the Acquiror Company is required to perform or to comply with pursuant to this
Agreement (considered collectively), and each of these covenants and obligations (considered individually), must have been performed
and complied with in all respects.

 

9.2.2                  
Each document required to be delivered by the Acquiror Company pursuant to this Agreement must have been delivered.

 

9.3              No Force Majeure Event. There shall not have been any delay, error,
failure or interruption in the conduct of the business of the Acquiror Company, or any loss, injury, delay, damage, distress,
or other casualty, due to force majeure including but not limited to (a) acts of God; (b) fire or explosion; (c) war, acts of
terrorism or other civil unrest; or (d) national emergency.

 

9.4             
Certificate of Officer. The Acquiror Company will have delivered to the Company a certificate, dated the Closing
Date, executed by an officer of the Acquiror Company on the Acquiror Company’s behalf, certifying the satisfaction of the
conditions specified in Sections 9.1 and 9.2, relating to the Acquiror Company.

 

     32

     

    

 

9.5     
         Consents.

 

9.5.1                 
All material consents, waivers, approvals, authorizations or orders required to be obtained, and all filings required to
be made, by the Acquiror Company for the authorization, execution and delivery of this Agreement and the consummation by it of
the transactions contemplated by this Agreement, shall have been obtained and made by the Acquiror Company, except where the failure
to receive such consents, waivers, approvals, authorizations or orders or to make such filings would not have a Material Adverse
Effect on the Acquiror Company.

 

9.6             
Documents. The Acquiror Company must have caused the following documents to be delivered to the Company and/or the
Shareholders:

 

9.6.1                  
 Delivery to each Shareholder a Certificate evidencing such Shareholder’s pro rata share of the Closing Acquiror Company
Shares (as set forth in Exhibit A);

 

9.6.2                  
each of the Transaction Documents to which the Acquiror Company is a party, duly executed;

 

9.6.3                  
evidence, reasonably acceptable to the Company, that the Director Nominee shall become a member of the Acquiror Company
Board, effective as of the Closing;

 

9.6.4                  
a statement from the Acquiror Company’s transfer agent regarding the number of issued and outstanding shares of common
stock immediately before and after the Closing, and, such other documents as the Company may reasonably request for the purpose
of (A) evidencing the accuracy of any of the representations and warranties of the Acquiror Company pursuant to Section 9.1,
(B) evidencing the performance of, or compliance by the Acquiror Company with, any covenant or obligation required to be performed
or complied with by the Acquiror Company, (C) evidencing the satisfaction of any condition referred to in this Section 9.1,
or (D) otherwise facilitating the consummation or performance of any of the transactions contemplated by this Agreement.

 

9.7         
     No Proceedings. Since the date of this Agreement, there must not have been commenced
or threatened against the Acquiror Company, the Company or any Shareholder, or against any Affiliate thereof, any Proceeding
(which Proceeding remains unresolved as of the date of this Agreement) (a) involving any challenge to, or seeking damages or
other relief in connection with, any of the transactions contemplated hereby, or (b) that may have the effect of preventing,
delaying, making illegal, or otherwise interfering with any of the transactions contemplated hereby.

 

9.8      
        No Claim Regarding Stock Ownership or Consideration. There must not
have been made or threatened by any Person, other than persons listed on Schedule I hereto, any claim asserting that
such Person (a) is the holder of, or has the right to acquire or to obtain beneficial ownership of the Acquiror Company
Common Stock or any other stock, voting, equity, or ownership interest in, the Acquiror Company or (b) is entitled to all or
any portion of the Acquiror Company Shares.

 

     33

     

    

 

SECTION
X

INDEMNIFICATION; REMEDIES

 

10.1       Indemnification by Principals. Each Principal, severally and not jointly in proportion to each such Principal’s pro
rata share of the Acquiror Company Shares, will indemnify and hold harmless the Acquiror Company and its directors, officers,
shareholders, employees, agents, subsidiaries and affiliates (the “Acquiror Company Indemnified Persons”),
and will reimburse the Acquiror Company Indemnified Persons for, any loss, liability, claim, damage or expense, including reasonable
out-of-pocket costs of investigation and defense of claims and reasonable attorneys’ fees and expenses (collectively, “Losses”)
arising or resulting from or in connection with any of the following:

 

10.1.1           any breach of any representation or warranty of the Company and/or its Subsidiaries set forth in Section V of this Agreement;

 

10.1.2           any breach of any representation or warranty of such Principal (and not of any other Principal) set forth in Section IV
and Section V of this Agreement; or

 

10.1.3           any breach of any covenant or obligation of the Company, its Subsidiaries and/or the Shareholders’ Representative in this
Agreement.

 

10.2       Indemnification By Acquiror Company. The Acquiror Company will indemnify and hold harmless the Shareholders and their respective
directors, officers, shareholders, employees, agents, subsidiaries and affiliates (collectively, the “Shareholder Indemnified
Persons”) and will reimburse the Shareholder Indemnified Persons for, any Losses arising or resulting from or in connection
with any of the following:

 

10.2.1           any breach of any representation or warranty made by the Acquiror Company in Section VI of this Agreement; or

 

10.2.2           any breach of any covenant or obligation of the Acquiror Company in this Agreement.

 

10.3       Indemnification Limitation – Survival.

 

10.3.1           The representations and warranties contained in this Agreement shall survive the Closing and shall continue in full force and
effect until the date that is twelve (12) months following the Closing Date.

 

10.3.2           All covenants and other obligations of each of the Company, the Company’s Subsidiaries and Acquiror Company contained in
this Agreement shall survive the Closing and continue in full force and effect until such covenants or obligations expire, are
fully performed and satisfied, or otherwise until the expiration of the statute of limitations, in accordance with the respective
terms of such covenants and obligations set forth in this Agreement. None of the Acquiror Company Indemnified Persons and the
Shareholder Indemnified Persons may bring any claim for indemnification under this Section X after expiration of the time
period set forth in this Section 10.3 to which such claim relates. Notwithstanding anything to the contrary herein, any
claim asserted in good faith pursuant to and in compliance with this Section X prior to the expiration of the applicable
survival period shall survive until such claim is fully and finally resolved.

 

    34 

     

    

 

10.3.3           The right to indemnification based upon such representations, warranties, covenants and obligations shall not be affected by any
examination, inspection, audit or other investigation conducted by any Person with respect to, or any knowledge acquired at any
time with respect to, the accuracy or inaccuracy of or compliance with any such representation, warranty, covenant or obligation.

 

10.4       Indemnification Limitation – Deductible. The Principals shall have no obligation to indemnify the Acquiror Company
Indemnified Persons under Section 10.1.1-10.1.3, and no indemnification claims shall be brought against the Principals
under Section 10.1.1-10.1.3, until the aggregate amount of Losses incurred by Acquiror Company Indemnified Persons exceeds
$10,000 (the “Deductible”), at which point the Principals will be obligated to indemnify the Acquiror Company
Indemnified Persons from and against all Losses incurred by such Acquiror Company Indemnified Persons in excess of the Deductible.
The Acquiror Company shall have no obligation to indemnify the Shareholder Indemnified Persons under Section 10.2.1-10.2.2,
and no indemnification claims shall be brought against the Acquiror Company under Section 10.2.1-10.2.2, until the
aggregate amount of Losses incurred by the Shareholder Indemnified Persons exceeds the Deductible, at which point the Acquiror
Company will be obligated to indemnify the Shareholder Indemnified Persons in excess of the Deductible.

 

10.5       Indemnification Limitation – Cap. The Principals shall have no obligation to indemnify the Acquiror Company Indemnified
Persons under Section 10.1.1-10.1.3 and no indemnification claims or any other claims shall be brought against the Principals
under Section 10.1.1-10.1.3, for an aggregate amount of Losses incurred by Acquiror Company Indemnified Persons in excess
of the value of the Escrow Shares determined in accordance with Section 10.6 (the “Indemnification Cap”)
and any such rights to indemnity shall be satisfied solely by recourse to the Escrow Shares. The Acquiror Company shall have no
obligation to indemnify the Shareholder Indemnified Persons under Section 10.2.1-10.2.2 and no indemnification claims or
any other claims shall be brought against the Acquiror Company under Section 10.2.1-10.2.2, for an aggregate amount of
Losses incurred by Shareholder Indemnified Persons in excess of the amount calculated by multiplying (a) a 5-day trailing VWAP
on the date the claim is brought, by (b) the total number of shares of Acquiror Company then outstanding. The Acquiror Company
shall have no obligation to indemnify the Shareholder Indemnified Persons for any Losses hereunder in excess of such amount.

 

10.6       Escrow Shares. To the extent that an Acquiror Company Indemnified Person makes any claim for indemnification pursuant to
Section 10.1, it shall make a claim against the Escrow Shares. In the event that any Acquiror Company Indemnified Person
sustains or incurs Losses for which it is entitled to indemnification under Section 10.1, such Losses shall be recovered
or paid by forfeiture of that number of Escrow Shares representing the amount of such claim until such Losses are paid or until
all of the Escrow Shares have been forfeited. The period during which claims for Losses may be made against the Escrow Shares
shall commence at the Closing and terminate on the date that is twelve (12) months after the date of this Agreement (the “Escrow
Period”). Notwithstanding anything contained herein to the contrary, the Escrow Agent shall continue to retain such
portion of the Escrow Shares at the conclusion of the Escrow Period as shall be necessary to satisfy any unresolved or unsatisfied
claims for Losses hereunder until such claims for Losses have been resolved or satisfied. Any Escrow Shares that have not been
forfeited to satisfy the Shareholders’ indemnity obligations, if any, shall be released from escrow and returned to the
Shareholders pursuant to the Share Escrow Agreement. For purposes of determining the number of Escrow Shares to be forfeited to
satisfy an indemnity obligation of the Shareholders, the value per Escrow Share shall be equal to the 5-day trailing VWAP on the
day of forfeiture.

 

    35 

     

    

 

10.7       Indemnification Procedures.

 

10.7.1           An indemnified party hereunder (the “Claiming Party”) shall give the indemnifying party (“Indemnifying
Party”) prompt written notice (“Third Party Claim Notice”) of any claim of a third party (a “Third
Party Claim”) as to which the Claiming Party proposes to demand indemnification hereunder, within thirty (30) days after
learning of such Third Party Claim (or within such shorter time as may be necessary to give the Indemnifying Party a reasonable
opportunity to respond to such claim) (such period is referred to herein as the “Indemnification Notice Period”).
The Third Party Claim Notice shall (i) describe the claim in reasonable detail, and (ii) indicate the amount (estimated, if necessary,
and to the extent feasible) of the Losses that have been or may be suffered by the Claiming Party. The failure to give a Third
Party Claim Notice to the Indemnifying Party shall not relieve the Indemnifying Party of any liability hereunder unless the Indemnifying
Party was prejudiced thereby under this Section X, and then only to the extent of such prejudice. The Indemnifying Party
must provide, within thirty (30) days, written notice to the Claiming Party that it is either (i) assuming responsibility for
the Third Party Claim, or (ii) disputing the claim for indemnification against it (the “Indemnification Notice”).

 

10.7.2           If the Indemnifying Party provides an Indemnification Notice to the Claiming Party within the Indemnification Notice Period that
it assumes responsibility for the Third Party Claim, the Indemnifying Party shall have the right to assume and conduct the defense
of such Third Party Claim at its own expense; provided, however, that the Claiming Party will be allowed a reasonable
opportunity to participate in the defense of such Third Party Claim with its own counsel and at its own expense; and provided further that in the event that the interests of the Claiming Party and the Indemnifying Party are, or may reasonably become,
in conflict with, or adverse to one another, with respect to such Third Party Claim, the Claiming Party may retain its own counsel
at the Indemnifying Party’s expense (but limited to reasonable attorneys’ fees and expenses) with respect to such
Third Party Claim. In the event the Indemnifying Party assumes and conducts the defense on behalf of the Claiming Party, the Indemnifying
Party shall, subject to Sections 10.3, 10.4, 10.5 and 10.6, as applicable, be deemed to acknowledge
that it is responsible to the Claiming Party for any damages as a result of such Third Party Claim, and may settle such Third
Party Claim, but shall not, without the consent of the Claiming Party (which consent shall not be unreasonably withheld or delayed),
agree to any settlement that does not include a provision whereby the plaintiff or claimant in the matter releases the Claiming
Party from all liability with respect thereto or agree to any material relief other than money damages (and a full release related
thereto). If the Indemnifying Party does not assume the defense of such Third Party Claim in the manner provided above and does
not dispute the claim for indemnification against it, or if after commencing or undertaking any such defense, fails to prosecute
diligently or withdraws from such defense, the Claiming Party shall have the right to undertake the defense or settlement thereof,
and the Claiming Party may defend against, or enter into any settlement with respect to, the matter in any manner the Claiming
Party reasonably may deem appropriate; provided that any such settlement of such Third Party Claim must include a provision
whereby the plaintiff or claimant in the matter releases the Claiming Party and the Indemnifying Party from all liability with
respect thereto; and provided further that the Indemnifying Party will be allowed a reasonable opportunity to participate
in the defense of such Third Party Claim with its own counsel and at its own expense. In the event that (x) a final judgment or
order in favor of such third party in respect of such Third Party Claim is rendered against the Claiming Party, that is not subject
to appeal or with respect to which the time to appeal has expired without an appeal having been made, or (y) such Third Party
Claim is settled in accordance with this Section 10.7.2, resulting in liability on the part of the Claiming Party, then
subject to the limitations set forth in Sections 10.3, 10.4, 10.5 and 10.6, the Indemnifying Party
shall pay the amount of such liability (which payment, in the case of indemnification by the Shareholders, shall be made by forfeiture
of that number of Escrow Shares or, if all such Escrow Shares have been forfeited and subject to the limitations of Section
10.5, the Acquiror Company Shares, having a value (as determined in accordance with Section 10.6) equal to such liability.

 

    36 

     

    

 

10.7.3           In the event any Claiming Party should have a claim against any Indemnifying Party for indemnification of Losses hereunder other
than in connection with a Third Party Claim, such Claiming Party shall deliver prompt notice of such claim to the Indemnifying
Party within thirty (30) days after learning of such claim (or within such shorter time as may be necessary to give the Indemnifying
Party a reasonable opportunity to respond to such claim), stating in reasonable detail the nature and basis of such claim and
providing copies of the relevant documents evidencing such claim (if any), the amount of the claim (estimated, if necessary, and
to the extent feasible), and the basis for the indemnification sought. Notwithstanding the foregoing, the failure of the Claiming
Party to give such notice to the Indemnifying Party shall not relieve the Indemnifying Party of any liability hereunder unless
the Indemnifying Party was prejudiced thereby under this Section X, and then only to the extent of such prejudice. If the
Indemnifying Party notifies the Claiming Party that it does not dispute the claim described in such notice or fails to notify
the Claiming Party within thirty (30) days after delivery of such notice by the Claiming Party whether the Indemnifying Party
disputes the claim described in such notice, the Loss in the amount specified in the Claiming Party’s notice shall be conclusively
deemed a liability of the Indemnifying Party and, subject to the limitations set forth in Sections 10.3, 10.4, 10.5
and 10.6, the Acquiror Company shall pay the amount of such Loss to the Shareholder Indemnified Persons on demand,
or the Shareholders shall agree to a forfeiture of that number of Escrow Shares or, if all such Escrow Shares have been forfeited
and subject to the limitations of Section 10.5, the Acquiror Company Shares, having a value (as determined in accordance
with Section 10.6) equal to the Loss incurred by the Acquiror Company Indemnified Persons, as applicable. If the Indemnifying
Party has timely disputed its liability with respect to such claim, the dispute shall be resolved by mutual agreement of the Claiming
Party and Indemnifying Party, or in the absence of such agreement, by arbitration of competent jurisdiction and not subject to
further appeal. Notwithstanding anything to the contrary contained herein, as applicable, the Acquiror Company shall pay the Shareholder
Indemnified Persons, or the Shareholders shall agree to a forfeiture of that number of Escrow Shares or, if all such Escrow Shares
have been forfeited and subject to the limitations of Section 10.5, the Acquiror Company Shares, having a value (as determined
in accordance with Section 10.6 above) equal to the amount of any such Loss no later than ten (10) business days following
the determination of the Indemnifying Party’s liability (whether such determination is made pursuant to the procedures set
forth in this Section 10.7.3, by agreement between the Indemnifying Party and the Claiming Party or by final adjudication).

 

    37 

     

    

 

For
purposes of the procedures in this Section 10.7, to the extent the Claiming Party or Indemnifying Party is a Shareholder
(or such group collectively), all notices shall be provided to the Shareholders’ Representative and the Shareholders’
Representative shall be authorized to take any actions required or permitted of the Claiming Party or Indemnifying Party, as applicable.

 

10.8      Computation of Losses. For purposes of calculating any Losses suffered by an Indemnified Person hereunder (but, for the
avoidance of doubt, not for purposes of determining whether a breach has occurred that entitles indemnification under this Section
X), the amount of the Losses suffered by the Claiming Party shall be the net amount of the Loss so suffered after giving effect
to the aggregate value of any money or other assets with a readily determinable value (including, without limitation, proceeds
of insurance) realized by the Claiming Party in connection therewith.

 

10.9       Exclusive Remedy. Each of the parties hereto agrees that from and after the Closing, his, her or its exclusive remedy with
respect to any and all claims relating to breaches of covenants, representations and warranties of this Agreement shall be indemnification
pursuant to this Section X.

 

10.10     Subrogation. Upon making any indemnification payment under this Section X, the Indemnifying Party will, to the extent
of such payment, be subrogated to all rights of the Claiming Party against any third party in respect of the Losses to which such
payment relates.

 

10.11     Consideration Adjustment. All indemnification payments made hereunder will be treated by all parties as adjustments to
the consideration payable hereunder.

 

10.12     Indemnification Limitation. Neither the Shareholders, on the one hand, nor the Acquiror Company, on the other hand, shall
have any obligation to indemnify the Acquiror Company Indemnified Persons or Shareholder Indemnified Persons, as applicable, from
and against any punitive or exemplary damages or any damages based on any type of multiple relating to the breach or alleged breach
of this Agreement, except in the case of any such damages that are payable to a third party in respect of a Third Party Claim
that gives rise to indemnification rights hereunder. Any Losses for which any of the Acquiror Company Indemnified Persons or Shareholder
Indemnified Persons, as applicable, are entitled to indemnification under this Section X shall be determined without duplication
of recovery by reason of the state of facts giving rise to such Losses constituting a breach of more than one representation,
warranty, covenant or agreement.

 

SECTION
XI

REGISTRATION RIGHTS

 

11.1       Registration of Acquiror Company Shares. Notwithstanding the Lock-Up Period, the Acquiror Company shall take any and all
actions, including without limitation, drafting, filing and keeping effective a registration statement under the Securities Act,
necessary to register and facilitate the sale of the Registrable Securities, for sale by any and all Shareholders immediately
upon expiration of the Lock-Up Period in full compliance with the Securities Act.

 

    38 

     

    

 

11.2       Obligations of the Acquiror Company. The Acquiror Company shall, as expeditiously as reasonably possible:

 

11.2.1          prepare and file with the Commission such amendments and supplements to such registration statement, and the prospectus used in
connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition
of the Registrable Securities;

 

11.2.2          furnish to the selling Shareholders such numbers of copies of a prospectus, including a preliminary prospectus, as required by
the Securities Act, and such other documents as the Shareholders may reasonably request in order to facilitate their disposition
of their Acquiror Company Shares;

 

11.2.3          use its commercially reasonable efforts to register and qualify the Registrable Securities under such other securities or blue-sky
laws of such jurisdictions as shall be reasonably requested by the selling Shareholders; provided, however, that
the Acquiror Company shall not be required to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions, unless the Acquiror Company is already subject to service in such jurisdiction and except as may
be required by the Securities Act;

 

11.2.4          in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the underwriter(s) of such offering;

 

11.2.5          use its commercially reasonable efforts to cause all such Registrable Securities to be listed on a national securities exchange
or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Acquiror
Company are then listed;

 

11.2.6          provide a transfer agent and registrar for all Registrable Securities and provide a CUSIP number for all such Acquiror Company
Shares, in each case not later than the effective date of such registration;

 

11.2.7          promptly make available for inspection by the selling Shareholders, any underwriter(s) participating in any disposition pursuant
to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by
the selling Shareholders, all financial and other records, pertinent corporate documents, and properties of the Acquiror Company,
and cause the Acquiror Company’s officers, directors, employees, and independent accountants to supply all information reasonably
requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

    39 

     

    

 

11.2.8           notify each selling Shareholder, promptly after the Acquiror Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been
filed; and

 

11.2.9           after such registration statement becomes effective, notify each selling Shareholder of any request by the Commission that the
Acquiror Company amend or supplement such registration statement or prospectus.

 

SECTION
XII

SHAREHOLDERS’ REPRESENTATIVE

 

12.1       Each Shareholder by virtue of the approval and adoption of this Agreement or by accepting any consideration payable hereunder
shall be deemed to have agreed to appoint the Shareholders’ Representative for and on behalf of the Shareholders to do or
refrain from doing all further acts and things, and to execute all such documents, as the Shareholders’ Representative shall
deem necessary or appropriate. Upon and subject to the terms of this Agreement, the Shareholders’ Representative shall have
the power and authority to:

 

12.1.1           act for the Shareholders with regard to all matters pertaining to this Agreement or any of the other Transaction Documents to
which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is a party;

 

12.1.2           act for the Shareholders to transact matters of litigation, disputes or proceedings pertaining to this Agreement or any of the
other Transaction Documents to which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is a party;

 

12.1.3           execute and deliver all amendments, waivers, ancillary agreements, certificates and documents that the Shareholders’ Representative
deems necessary or appropriate in connection with the consummation of the transactions contemplated by this Agreement or any of
the other Transaction Documents to which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is a party;

 

12.1.4           receive funds, make payments of funds, and give receipts for funds;

 

12.1.5           do or refrain from doing, on behalf of the Shareholders, any further act or deed that the Shareholders’ Representative deems
necessary or appropriate in the Shareholders’ Representative’s discretion relating to the subject matter of this Agreement
or any of the other Transaction Documents to which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is
a party, in each case as fully and completely as the Shareholders could do in such circumstance;

 

12.1.6           give and receive all notices required to be given or received by the Shareholders under this Agreement or any of the other Transaction
Documents to which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is a party;

 

    40 

     

    

 

12.1.7           give any written direction that can be given by any Shareholder under the terms of this Agreement or any of the other Transaction
Documents to which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is a party;

 

12.1.8           agree to, negotiate, enter into settlements and compromises and/or comply with arbitration awards and court orders with respect
to claims for indemnification made by an Acquiror Company Indemnified Person under Section X; and

 

12.1.9           receive service of process in connection with any claims under this Agreement and/or any of the other Transaction Documents to
which the Company, any of its Subsidiaries or a Shareholder (in such capacity) is a party.

 

Such
agency may be changed by the Shareholders from time-to-time with the consent of the Shareholders holding a majority of the Acquiror
Company Shares then outstanding. Notwithstanding the foregoing, the Shareholders’ Representative may resign at any time
by providing written notice of intent to resign to the Shareholders, which resignation shall be effective upon thirty (30) calendar
days following delivery of such written notice or the appointment of a successor by the Shareholders holding a majority of the
Acquiror Company Shares then outstanding. If the Shareholders’ Representative shall be removed, resign or otherwise be unable
to fulfill its responsibilities hereunder, the Shareholders holding a majority of the Acquiror Company Shares then outstanding
shall appoint a successor to the Shareholders’ Representative, and shall promptly thereafter notify Acquiror Company of
the identity of such successor. Any such successor shall succeed the former Shareholders’ Representative as the Shareholders’
Representative hereunder. No bond shall be required of the Shareholders’ Representative. A decision, act, consent or instruction
of the Shareholders’ Representative, including an amendment, extension or waiver of this Agreement pursuant to its authority
hereunder, shall constitute a decision of the Shareholders and shall be final, binding and conclusive upon the Shareholders, and
the Shareholders shall be deemed to have waived all defenses which may otherwise be available to the Shareholders to contest,
negate or disaffirm the action of the Shareholders’ Representative taken in good faith under this Agreement.

 

12.2       By executing this Agreement under the heading “Shareholders’ Representative,” the Shareholders’
Representative hereby (i) accepts its appointment and authorization to act as Shareholders’ Representative as attorney-in-fact
and agent on behalf of the Shareholders in accordance with the terms of this Agreement and (ii) agrees to perform its obligations
under, and otherwise comply with, this Section XII.

 

    41 

     

    

 

12.3       Neither the Shareholders’ Representative nor its members, managers, directors, officers, contractors, agents and employees
(collectively, the “Shareholders’ Representative Group”) shall be liable to any former Shareholder for
any act done or omitted hereunder as the Shareholders’ Representative without gross negligence or willful misconduct or
bad faith (and any act done or omitted pursuant to the bona fide good faith advice of counsel, accountants and other professionals
and experts retained by the Shareholders’ Representative shall be conclusive evidence of good faith). To the fullest extent
permitted by applicable Laws, the Shareholders shall severally indemnify the Shareholders’ Representative Group and defend
and hold it harmless against any loss, liability, claim, damage, fee, fine, cost, judgment, amount paid in settlement or expense
incurred without gross negligence, willful misconduct or bad faith on the part of the Shareholders’ Representative and arising
out of or in connection with the acceptance or administration of its duties hereunder, including any out-of-pocket costs and expenses
and legal fees and other legal and skilled professionals’ costs reasonably incurred by the Shareholders’ Representative
and in connection with seeking recovery from insurers. The Shareholders acknowledge that the Shareholders’ Representative
shall not be required to expend or risk its own funds or otherwise incur any financial liability in the exercise or performance
of any of its powers, rights, duties or privileges or administration of its duties. Furthermore, the Shareholders’ Representative
shall not be required to take any action unless the Shareholders’ Representative has been provided with funds, security
or indemnities which, in its determination, are sufficient to protect the Shareholders’ Representative against the costs,
expenses and liabilities which may be incurred by the Shareholders’ Representative in performing such actions. The Shareholders’
Representative shall only have the duties expressly stated in this Agreement and shall have no other duty, express or implied.
The Shareholders’ Representative may engage attorneys, accountants, investment bankers, advisors, consultants and clerical
personnel and obtain such other professional and expert assistance, and maintain such records, as the Shareholders’ Representative
may deem necessary or desirable. The Shareholders’ Representative may in good faith rely conclusively upon information,
reports, statements and opinions prepared or presented by such professionals, and any action taken by the Shareholders’
Representative based on such reliance shall be deemed conclusively to have been taken in good faith.

 

12.4       All of the immunities granted to the Shareholders’ Representative under this Agreement shall survive his resignation or
removal and the Closing and/or any termination of this Agreement. The grant of authority provided for in this Section XII,
and the powers and immunities granted to the Shareholders’ Representative hereunder are coupled with an interest and shall
be irrevocable and survive the death, incompetence, bankruptcy or liquidation of the respective Shareholder and shall be binding
on any successor thereto.

 

SECTION
XIII

GENERAL PROVISIONS

 

13.1       Ownership of Common Stock. Upon signature by each Shareholder hereto, such Shareholder hereby represents, warrants and
covenants that the number of shares of Common Stock listed as owned by such Shareholder is true and correct as of the Closing
Date and hereby irrevocably approves the transfer of such Shares to the Acquiror Company, at Closing and pursuant to the terms
of this Agreement.

 

13.2       Expenses. Except as otherwise expressly provided in this Agreement, each party to this Agreement will bear its respective
expenses incurred in connection with the preparation, execution, and performance of this Agreement and the transactions contemplated
by this Agreement, including all fees and expenses of agents, representatives, counsel, and accountants. In the event of termination
of this Agreement, the obligation of each party to pay its own expenses will be subject to any rights of such party arising from
a breach of this Agreement by another party.

 

    42 

     

    

 

13.3       Notices. All notices, demands, consents, requests, instructions and other communications to be given or delivered or permitted
under or by reason of the provisions of this Agreement or in connection with the transactions contemplated hereby shall be in
writing and shall be deemed to be delivered and received by the intended recipient as follows: (i) if personally delivered, on
the business day of such delivery (as evidenced by the receipt of the personal delivery service), (ii) if mailed certified or
registered mail return receipt requested, two (2) business days after being mailed, (iii) if delivered by overnight courier (with
all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the overnight courier service
of recognized standing), or (iv) if delivered by facsimile transmission or electronic mail, on the business day of such delivery
if sent by 6:00 p.m. in the time zone of the recipient, or if sent after that time, on the next succeeding business day (as evidenced
by the printed confirmation of delivery generated by the sending party’s telecopier machine if by facsimile). If any notice,
demand, consent, request, instruction or other communication cannot be delivered because of a changed address of which no notice
was given (in accordance with this Section 13.3), or the refusal to accept same, the notice, demand, consent, request,
instruction or other communication shall be deemed received on the second business day the notice is sent (as evidenced by a sworn
affidavit of the sender). All such notices, demands, consents, requests, instructions and other communications will be sent to
the following addresses, email addresses, or facsimile numbers as applicable

 

	If
to Acquiror Company:

Inspyr Therapeutics, Inc.

31200 Via Colinas

        Suite
200

        Westlake
Village, CA 91362

        Telephone
No.:818-661-6302

        Fascimile
No.:818-661-6302

        Attention:
Christopher Lowe
	with
                                         a copy, which shall not constitute notice to:

         

        Silvestre
Law Group, P.C

        31200
Via Colinas #200

        Westlake
Village, CA 91362

        Attention:
        Raul Silvestre

         

	 	 	 
	 	If
to the Company:

        

Lewis & Clark Pharmaceuticals, Inc.

        1180
Seminole Trail, Ste 495

        Charlottesville,
CA 22901

Attention: Robert Thompson, CEO, PhD
	with
                                    a copy, which shall not constitute notice to:

         

        Pillsbury
Winthrop Shaw Pittman LLP 

        1650
Tysons Boulevard, 14th Floor

        McLean,
Virginia 22102-4856

        Attention:
Matthew B. Swartz, Esq.

	 	 	 

13.4       Arbitration. Any dispute or controversy under this Agreement (including any related to indemnification under Section
10.1) shall be settled exclusively by arbitration solely in the City of Chicago in accordance with the rules of the American
Arbitration Association then in effect. Judgment may be entered on the arbitration award in any court having jurisdiction.

 

13.5       Further Assurances. The parties agree (a) to furnish upon request to each other such further information, (b) to execute
and deliver to each other such other documents, and (c) to do such other acts and things, all as the other party may reasonably
request for the purpose of carrying out the intent of this Agreement and the documents referred to in this Agreement.

 

    43 

     

    

 

13.6       Waiver. The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither the failure
nor any delay by any party in exercising any right, power, or privilege under this Agreement or the documents referred to in this
Agreement will operate as a waiver of such right, power, or privilege, and no single or partial exercise of any such right, power,
or privilege will preclude any other or further exercise of such right, power, or privilege or the exercise of any other right,
power, or privilege. To the maximum extent permitted by applicable law, (a) no claim or right arising out of this Agreement or
the documents referred to in this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of
the claim or right unless it is in writing signed by the other party; (b) no waiver that may be given by a party will be applicable
except in the specific instance for which it is given; and (c) no notice to or demand on one party will be deemed to be a waiver
of any obligation of such party or of the right of the party giving such notice or demand to take further action without notice
or demand as provided in this Agreement or the documents referred to in this Agreement.

 

13.7       Entire Agreement and Modification. This Agreement and the Transaction Documents supersede all prior agreements between
the parties with respect to its subject matter and constitute (along with the other documents referred to in this Agreement) a
complete and exclusive statement of the terms of the agreement between the parties with respect to its subject matter. This Agreement
may not be amended except by a written agreement executed by the Company, the Acquiror Company and the Shareholders’ Representative.

 

13.8       Assignments, Successors, and No Third-Party Rights. No party may assign any of its rights under this Agreement without
the prior consent of the other parties. Subject to the preceding sentence, this Agreement will apply to, be binding in all respects
upon, and inure to the benefit of and be enforceable by the respective successors and permitted assigns of the parties. Except
as set forth in Section 10.1, nothing expressed or referred to in this Agreement will be construed to give any Person other
than the parties to this Agreement any legal or equitable right, remedy, or claim under or with respect to this Agreement or any
provision of this Agreement. This Agreement and all of its provisions and conditions are for the sole and exclusive benefit of
the parties to this Agreement and their successors and assigns.

 

13.9       Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction,
the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable
only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

 

13.10     Section Headings, Construction. The headings of Sections in this Agreement are provided for convenience only and will not
affect its construction or interpretation. All references to “Section” or “Sections” refer
to the corresponding Section or Sections of this Agreement. All words used in this Agreement will be construed to be of such gender
or number as the circumstances require. Unless otherwise expressly provided, the word “including” does not limit the
preceding words or terms.

 

13.11     Governing Law. This Agreement will be governed by the laws of the State of California without regard to conflicts of laws
principles.

 

    44 

     

    

 

13.12     Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original
copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.

 

[Signature
Pages Follow]

 

    45 

     

    

 

COUNTERPART
SIGNATURE PAGE

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Share Exchange Agreement as of the date first written above.

 

Acquiror
Company:

 

Inspyr Therapeutics, Inc.

	 	 	 
	Signed: 	 	 
	Printed name: Christopher Lowe	 
	Title: Chief Executive Officer	 

 

	Company:	 	Principals:	 
	 	 	 	 
	Lewis and Clark Pharmaceuticals,
    Inc.	 	 	 
	 	 	 	Robert Thompson	 
	Signed: 	 	 	 	 

	Printed name: 	 	 

	Title: 	 	 

 

	Shareholders’ Representative	 	 	 
	 	 	Larry Rodman	 
	 	 	 	 
	 	 	 	 
	Robert Thompson	 	John Montgomery	 
	 	 	 	 
	 	 	 	 
	 	 	Gretchen Montgomery	 

  

     

     

    

 

COUNTERPART
SIGNATURE PAGE

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Share Exchange Agreement as of the date first written above.

		 		 
	Shareholders: 	 	 	 
	 	 	 	 
	Signed:	 	 	 
	 	 	 	 
	 	 	 	 
	Printed name:	 	 	 
	 	 	 	 
	 	 		 
	Title (if applicable):	 	 	 
	 	 	 	 
	 	 	 	 
	Company (if applicable):	 	 	 
	 	 	 	 

 

     

     

    

 

SCHEDULE
I

 

Shareholders
of Company:

 

     

     

    

 

EXHIBIT
A

 

SHARES
AND ACQUIROR COMPANY SHARES TO BE EXCHANGED

 

     

     

    

 

EXHIBIT
B

 

Form
of Employment Agreement

 

     

     

    

 

EXHIBIT
C

 

[RESERVED]

 

     

     

    

 

EXHIBIT
D

ACCREDITED INVESTOR REPRESENTATIONS

 

     

     

    

EXHIBIT
E

 

COMPANY
DISCLOSURE SCHEDULES

 

     

     

    

 

EXHIBIT
F

 

ACQUIROR
COMPANY DISCLOSURE SCHEDULESExhibit 10.2

 

SHARE ESCROW AGREEMENT

 

This SHARE ESCROW AGREEMENT (this
“Agreement”) dated as of this ____ day of July 2017 by and among INSPYR THERAPEUTICS, INC., a Delaware
corporation (the “Company”), having an address at 31200 Via Colinas #200, Westlake Village, CA 91362, ROBERT
D. THOMPSON, LARRY E. RODMAN, JOHN MONTGOMERY AND GRETCHEN MONTGOMERY, each individuals (the “Principals”),
each having address set forth on Schedule I hereto, and SILVESTRE LAW GROUP, P.C. (the “Escrow Agent”),
a California Professional Corporation, having an office at 31200 Via Colinas #200, Westlake Village, CA 91362. All capitalized
terms not herein defined shall have the meaning ascribed to them in that certain Share Exchange Agreement, of even date herewith
and as amended or supplemented from time-to-time, including all attachments, schedules and exhibits thereto (the “Exchange
Agreement”).

 

W I T N E S S E T H:

 

WHEREAS, pursuant
to the terms of the Exchange Agreement, entered into by and between the Company, Lewis and Clark Pharmaceuticals, Inc., a Virginia
corporation (“L&C”), the Principals and the shareholders of L&C, the Company is issuing certain shares
of its common stock, par value $0.0001 per share (“Common Stock”) in exchange for all of the issued and outstanding
capital stock of L&C;

 

WHEREAS, pursuant
to the Exchange Agreement, the Principals will receive such number of shares of Common Stock of the Company as contained in Schedule
I under the heading “Total Shares Received”;

 

WHEREAS, pursuant
to certain indemnification provisions contained in Section X of the Exchange Agreement, the Principals have agreed to indemnify
the Company and certain persons related thereto, through the escrow of such number of shares of Common Stock of the Company issued
to the Principals as contained in Schedule I under the heading “Escrow Shares”;

 

WHEREAS, the
Company and Principals desire to establish an escrow account with the Escrow Agent into which the Company and Principals agree
that the Escrow Shares, issued in the name of the applicable Principals, shall be deposited with the Escrow Agent pursuant to the
instructions herein, and the Escrow Agent is willing to accept said the Escrow Shares in accordance with the terms hereinafter
set forth;

 

WHEREAS, the
Company and Principals each, severally and not jointly, represent and warrant to the Escrow Agent that each will comply with all
of their respective obligations under applicable state and federal securities laws and regulations with respect to the transactions
contemplated in the Exchange Agreement and will further comply with their respective obligations under the Exchange Agreement with
respect to the Escrow Shares; and

 

WHEREAS, the
Company and Principals each, severally and not jointly, represent and warrant to the Escrow Agent that such party has not stated
to any individual or entity that the Escrow Agent’s duties will include anything other than those duties stated in this Agreement.

 

     

     

    

 

NOW, THEREFORE,
IT IS AGREED as follows:

 

1.             Delivery
of Escrow Shares. On the Closing Date, the Principals will cause certificates representing the Escrow Shares (issued in the
name of the applicable Principals) to be deposited, along with a stock power executed by the Principals, with the Escrow Agent
(the “Escrow Account”). Such Escrow Shares shall be held by the Escrow Agent pursuant to the terms of this Agreement.

 

2.             Disbursement
of Escrow Shares. The Escrow Shares shall be disbursed by the Escrow Agent in accordance with the following:

 

(a)       In
the event that the Escrow Agent is informed in writing by the Company in good faith during the period of twelve (12) months following
the Closing Date (“Survival Period”) that an Acquiror Company Indemnified Person has duly asserted a claim under
Section X of the Exchange Agreement (“Claim(s)”) prior to the expiration of the Survival Period that remains
unresolved or unsatisfied as of such expiration, the Escrow Agent will not release such portion of the Escrow Shares as shall be
necessary to satisfy such unresolved or unsatisfied Claim until the final adjudication of such Claim. To the extent the amount
of all unresolved or unsatisfied Claims as of the expiration of Survival Period shall be less than the then-value of the Escrow
Shares (which value shall be determined in accordance with Section X of the Exchange Agreement), the Escrow Agent shall promptly
thereafter (but in no event more than three (3) days after such written notice) release and transfer to the respective Principals
such other portion of the Escrow Shares, ratably based on their ownership of the Escrow Shares. Subsequent to the final adjudication
of any such Claim(s), and based on documentation reasonably satisfactory to the Escrow Agent, but not earlier than five (5) days
after informing the Company and the Principals in writing of the proposed disbursement, the Escrow Agent shall disburse (i) such
portion of the Escrow Shares in the Escrow Account to the Company necessary to cover any Losses in excess of the Deductible for
such Claim(s) as contained in Section X of the Exchange Agreement and (ii) the remaining portion of the Escrow Shares in the Escrow
Account to the respective Principals. In the event either the Company or either of the Principals disputes in good faith any aspect
of a proposed disbursement, the Company, Principals and the Escrow Agent shall cooperate in good faith to resolve such dispute.

 

(b)       At
the end of the Survival Period, or if Claim(s) are being adjudicated, then upon the date of such final adjudication of the remaining
Claim(s), the remaining Escrow Shares not disbursed to cover Losses pursuant to Section 2(a) hereof, as well as the executed stock
powers in possession of the Escrow Agent, will be disbursed to the respective Principals.

 

3.             Acceptance
by Escrow Agent. The Escrow Agent hereby accepts and agrees to perform its obligations hereunder, provided that:

 

(a)       The
Escrow Agent may act in reliance upon any signature believed by it to be genuine, and may assume that any person who has been designated
by the Company to give any written instructions, notice or receipt, or make any statements in connection with the provisions hereof
has been duly authorized to do so. Escrow Agent shall have no duty to make inquiry as to the genuineness, accuracy or validity
of any statements or instructions or any signatures on statements or instructions. The names and true signatures of each individual
authorized to act singly on behalf of the Company and Principals, as applicable, are stated in Schedule II, which is attached
hereto and made a part hereof. The Company and Principals may each remove or add one or more of its respective authorized signers
stated on Schedule II by notifying the Escrow Agent of such change in accordance with this Agreement, which notice shall
include the true signature for any new authorized signatories.

 

    2 

     

    

 

(b)       The
Principals and the Company agree to indemnify and hold the Escrow Agent harmless from and against any and all claims, losses, costs,
liabilities, damages, suits, demands, judgments or expenses (including but not limited to reasonable attorney’s fees) claimed
against or incurred by Escrow Agent arising out of or related, directly or indirectly, to this Escrow Agreement unless caused by
the Escrow Agent’s negligence or willful misconduct.

 

(c)       In
the event that the Escrow Agent shall be uncertain as to its duties or rights hereunder, the Escrow Agent shall be entitled to
(i) refrain from taking any action other than to keep safely the Escrow Shares until it shall be directed otherwise by a court
of competent jurisdiction, or (ii) deliver the Escrow Shares to a court of competent jurisdiction.

 

(d)       The
Escrow Agent shall have no duty, responsibility or obligation to interpret or enforce the terms of any agreement other than Escrow
Agent’s obligations hereunder.

 

4.                         Resignation and Termination of
the Escrow Agent. The Escrow Agent may resign at any time by giving thirty (30) days’ prior written notice of such resignation
to the Principals and the Company. Upon providing such notice, the Escrow Agent shall have no further obligation hereunder except
to hold as depository the Escrow Shares that it receives until the end of such 30-day period. In such event, the Escrow Agent shall
not take any action, until the Company and Principals have collectively designated a banking corporation, trust company, attorney
or other person as successor. Upon receipt of such written designation signed by Principals and the Company, the Escrow Agent shall
promptly deliver the Escrow Shares to such successor and shall thereafter have no further obligations hereunder. If such instructions
are not received within thirty (30) days following the effective date of such resignation, then the Escrow Agent may deposit the
Escrow Shares held by it pursuant to this Agreement with a successor of its choice. In either case provided for in this section,
the Escrow Agent shall be relieved of all further obligations and released from all liability thereafter arising with respect to
the Escrow Shares.

 

5.             Termination.
The Company and Principals may terminate the appointment of the Escrow Agent hereunder upon written notice specifying the date
upon which such termination shall take effect, which date shall be at least thirty (30) days from the date of such notice. In the
event of such termination, the Company and Principals shall, within thirty (30) days of such notice, appoint a successor escrow
agent and the Escrow Agent shall, upon receipt of written instructions signed by the Company and Principals, turn over to such
successor escrow agent all of the Escrow Shares; provided, however, that if the Company and Principals fail to appoint
a successor escrow agent within such thirty (30)-day period, such termination notice shall be null and void and the Escrow Agent
shall continue to be bound by all of the provisions hereof. Upon receipt of the Escrow Shares, the successor escrow agent shall
become the escrow agent hereunder and shall be bound by all of the provisions hereof and the Escrow Agent shall be relieved of
all further obligations and released from all liability thereafter arising with respect to the Escrow Shares and under this Agreement.
Upon the disbursement of all the Escrow Shares pursuant to Section 2 of this Agreement, this Agreement shall automatically terminate.

 

    3 

     

    

 

6.                         [Reserved].

 

7.                         Compensation.
The Escrow Agent shall be entitled, for the duties to be performed by it hereunder, to a fee of $1,000.00, which fee shall be paid
by the Company upon the signing of this Agreement. In addition, the Company shall be obligated to reimburse Escrow Agent for all
fees, costs and expenses incurred or that become due in connection with this Agreement or the Escrow Account. Neither the modification,
cancellation, termination or rescission of this Agreement nor the resignation or termination of the Escrow Agent shall affect the
right of Escrow Agent to retain the amount of any fee which has been paid, or to be reimbursed or paid any amount which has been
incurred or becomes due, prior to the effective date of any such modification, cancellation, termination, resignation or rescission.

 

8.                         Notices. All notices, requests,
demands and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been
duly given if sent by hand-delivery, by facsimile (followed by first-class mail), by nationally recognized overnight courier service
or by prepaid registered or certified mail, return receipt requested, or via electronic mail (e-mail) to the addresses set forth
below:

 

If to Principals, see
their respective addresses on Schedule I.

 

If to the Company:

 

Inspyr Therapeutics,
Inc.

31200 Via
Colinas #200

Westlake
Village, CA 91362

Attention:
Christopher Lowe

Fax: 818-661-6302

 

If to Escrow Agent:

 

Silvestre Law Group,
P.C.

31200 Via Colinas #200

Westlake Village, CA
91362

Attention: Raul Silvestre

Fax: 805-553-9783

 

    4 

     

    

 

9.                         General.

 

(a)       This
Agreement shall be governed by and construed and enforced in accordance with the laws of the State of California applicable to
agreements made and to be entirely performed within such State, without regard to choice of law principles and any action brought
hereunder shall be brought in the courts of the State of California, located in the County of Ventura. Each party hereto irrevocably
waives any objection on the grounds of venue, forum nonconveniens or any similar grounds and irrevocably consents to service of
process by mail or in any manner permitted by applicable law and consents to the jurisdiction of said courts. Each
of the parties hereto hereby waives all right to trial by jury in any action, proceeding or counterclaim arising out of the transactions
contemplated by this Agreement.

 

(b)       This
Agreement sets forth the entire
agreement and understanding of the parties with respect to the matters contained herein and supersedes all prior agreements, arrangements
and understandings relating thereto.

 

(c)       All
of the terms and conditions of this Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the parties
hereto, as well as their respective successors and assigns.

 

(d)       This
Agreement may be amended, modified, superseded or canceled, and any of the terms or conditions hereof may be waived, only by a
written instrument executed by each party hereto or, in the case of a waiver, by the party waiving compliance. The failure of any
party at any time or times to require performance of any provision hereof shall in no manner affect its right at a later time to
enforce the same. No waiver of any party of any condition, or of the breach of any term contained in this Agreement, whether by
conduct or otherwise, in any one or more instances shall be deemed to be or construed as a further or continuing waiver of any
such condition or breach or a waiver of any other condition or of the breach of any other term of this Agreement. No party may
assign any rights, duties or obligations hereunder unless all other parties have given their prior written consent.

 

(e)       If
any provision included in this Agreement proves to be invalid or unenforceable, it shall not affect the validity of the remaining
provisions.

 

(f)       This
Agreement and any modification or amendment of this Agreement may be executed in several counterparts or by separate instruments
and all of such counterparts and instruments shall constitute one agreement, binding on all of the parties hereto.

 

10.                       Form of Signature. The parties
hereto agree to accept a facsimile or electronic mail (e-mail) transmission copy of their respective actual signatures as evidence
of their actual signatures to this Agreement and any modification or amendment of this Agreement.

 

11.                       No Third-Party Beneficiaries.
This Agreement is solely for the benefit of the parties and their respective successors and permitted assigns, and no other person
has any right, benefit, priority or interest under or because of the existence of this Agreement.

 

    5 

     

    

 

[Signature Page Follows]

 

    6 

     

    

 

IN WITNESS WHEREOF, the parties
have duly executed this Share Escrow Agreement as of the date first set forth above.

 

	INSPYR THERAPEUTICS, INC.	 	PRINCIPALS
	 	 	 
	By:	 	 	 By:	 
	 	Name:
Title:	 	 	Name: Robert D. Thompson

 

	 	 By:	 
	 	 	Name: Larry
E. Rodman
	 	 	 
	 	 By:	 
	 	 	Name: John Montgomery
	 	 	 
	 	 By:	 
	 	 	Name: Gretchen
Montgomery

 

	SILVESTRE LAW GROUP, P.C.	 
	 	 	 
	By:	 	 
	 	Name: Raul Silvestre

Title: Managing Partner	 

 

    7 

     

    

 

Schedule I 

 

    8 

     

    

 

Schedule II

 

    9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]